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5I Foreword
The problem of measuring drug use, a complex, hidden and often highly stigmatised 
behaviour, is a central component of the work carried out by the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA). No single measure provides a full picture 
of the drug situation, and our overall strategy has been to adopt a multi-indicator approach. 
A number of specific information sources have been developed for this purpose, each of 
which highlights a particular aspect of the phenomenon, and by combining these we can 
build up a more comprehensive analysis. Nonetheless, the challenges in this area remain 
considerable, and thus the advantage of adding another tool to the epidemiological toolkit 
cannot be overestimated.
To be useful for policy, information needs to be technically robust and timely. Given the 
dynamic nature of the drug situation, equally dynamic monitoring responses should be 
available. However, a common problem of established monitoring tools is that they are 
time-consuming and complex, and thus require the investment of considerable resources 
if they are to produce reliable results. And in some areas, such as national surveys, the 
intervals between successive measurements will often be measured in years. In contrast, 
a relatively new approach, based on the analysis of municipal wastewater for drugs and 
drug residues, provides us with the opportunity to obtain more timely information on 
geographical and temporal drug use patterns.
In 2007, when the wastewater analysis approach was still in its infancy, the EMCDDA 
recognised that this fast-developing discipline had the potential to complement and 
extend the existing epidemiological tools for estimating illicit drug use. In that year, the 
Centre organised the first expert meeting on ‘Assessing drugs in wastewater’, and 
followed this up in 2008 by publishing an EMCDDA Insights on the topic. Later, in 2012, 
the EMCDDA was the driving force behind the first European multicity project to 
investigate the potential of wastewater analysis for estimating drug use at the level of the 
community. Using a common sampling approach, the project generated comparable data 
from over 25 European cities. The following year, in collaboration with the SEWPROF 
project, the EMCDDA organised ‘Testing the waters’, the first international 
multidisciplinary conference on detecting illicit drugs in wastewater; a second conference 
was held in October 2015. These initiatives brought together experts from a diverse range 
of disciplines to discuss future opportunities for integrating wastewater analysis into drug 
epidemiology. Indeed, a multidisciplinary approach is a central requirement for developing 
this new field, and researchers working in areas as diverse as chemistry, physiology, 
sewage engineering, statistics and drug epidemiology, to name a few, are contributing to 
our knowledge. 
Wastewater-based epidemiology has now demonstrated that it has the potential to 
become an important adjunct to established drug monitoring tools. Its ability to deliver 
near-real-time data is particularly relevant to the mercurial nature of today’s drug problem. 
By being able to detect changes in drug use patterns over time and as they occur, 
wastewater analysis can help health and treatment services in a number of ways. Alerting 
hospitals to the identities of new psychoactive substances being used in nightlife settings 
and predicting changes in treatment needs based on longer-term monitoring are but two 
potential examples. 
The considerable methodological developments that have occurred in wastewater-based 
epidemiology over the past 8 years have both highlighted that the EMCDDA’s interest in 
this area of study was not misplaced and underlined the importance of the original Insights 
publication Assessing illicit drugs in wastewater: Potential and limitations of a new 
monitoring approach. At the same time, they have rendered that original study obsolete: 
outdated and in need of replacement. To fill this need, the EMCDDA commissioned the 
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present publication, which I am proud to introduce. Based on the contributions to the most 
recent ‘Testing the waters’ conference, this publication presents a comprehensive review 
of the state of the art in wastewater-based drug epidemiology in Europe. 
Alexis Goosdeel
Director, EMCDDA
7I Executive summary
I Background
Monitoring illicit drug use is difficult because of the hidden and complex nature of drug-
using behaviours. ‘Wastewater analysis’, or ‘wastewater-based epidemiology’, holds 
promise for complementing established methods of drug use measurement. Wastewater 
in municipal water treatment plants contains traces of chemicals that have been excreted 
and, most probably, consumed within the area served by a given sewer network. Detecting 
such residues in wastewater samples allows for non-invasive, near-real-time analysis of 
drug use. Wastewater analysis has some clear advantages over other approaches, as it is 
not subject to the biases associated with self-reported data and can better identify the 
true spectrum of drugs being consumed, which is particularly important as users are often 
unaware of the actual mix of substances they take. This tool also has the potential to 
provide timely information in short timeframes on geographical and temporal trends.
I Estimating community drug use through wastewater analysis
Wastewater-based epidemiology consists of several consecutive steps that allow 
researchers to identify and quantify target metabolic residues of illicit drugs in raw 
wastewater and back-calculate the amount of the corresponding illicit drugs that would 
have been consumed by the population served by the wastewater treatment plant. First, 
representative composite samples of raw wastewater are collected and analysed for 
selected substances. Second, the back-calculation of drug consumption is performed by 
calculating the daily sewer loads of target residues; this is done by multiplying the 
concentrations of the measured target residues by the daily flow rates of sewage. From 
this value, the total consumption of a drug is estimated by applying a specific correction 
factor, which considers the average excretion rate of a given drug residue and the 
molecular mass ratio of the parent drug to its metabolite. In a third step, daily values are 
divided by the number of people served by the treatment plant in order to facilitate 
comparison among cities. This value can be expressed in daily amounts (or daily doses) 
per thousand population.
However, the findings of such an analysis are subject to uncertainties, mainly associated 
with sampling, biomarker analysis and stability, back-calculation of drug use, and the 
estimation of population size. Efforts to minimise the possible errors and standardise all 
procedures have achieved some success and continue to be made. The adoption of a 
standardised procedure will also improve the credibility and scalability of studies by 
ensuring that data from different sources are more reliable and comparable. Notably, the 
first Europe-wide study, performed in 2011 by the Sewage Analysis CORe group Europe 
(SCORE) network, provided a comprehensive insight into the uncertainties associated 
with all of these procedures. As a result, the group established a best-practice protocol 
with regard to sampling, sample handling, chemical analysis, back-calculation and data 
reporting. This protocol has been revised and updated during subsequent analytical 
campaigns in Europe, which were conducted annually.
I Application of wastewater-based epidemiology worldwide
Wastewater-based epidemiology has been applied in many countries to monitor the use of 
most of the commonly used illicit drugs. This worldwide application of wastewater-based 
epidemiology has demonstrated its potential for monitoring the use of cocaine, cannabis, 
amphetamine, methamphetamine and MDMA (3,4-methylenedioxymethamphetamine). 
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These studies detected geographical differences in drug use patterns, which were mostly 
consistent with data obtained by other approaches. Moreover, wastewater analysis has 
proven able to detect local and temporal patterns of drug use, demonstrating its potential 
to provide information that is complementary to that provided by standard techniques.
The detection of new psychoactive substances and the estimation of their use are 
challenges for drug epidemiology, including wastewater analysis. Pharmacokinetic data for 
most new psychoactive substances are essentially non-existent, as such compounds 
appear on the market at a rapid rate and the use levels of any particular substance are 
relatively low. Three conceptual approaches for dealing with new psychoactive substances 
using biomarkers in wastewater are presented in this report.
To date, few attempts have been made to compare drug use estimates obtained through 
wastewater analysis with conventional epidemiological data, obtained from population 
surveys. Although complicated and fraught with difficulties and limitations, comparing 
different approaches offers the possibility to cross-check data quality and accuracy, since 
each method tackles the task with different tools, and, therefore, combining different 
approaches should provide a more comprehensive assessment of drug use in a specific 
community. Some of the first attempts to compare results for cocaine use obtained using 
these two approaches are presented and discussed in this report. The first study was 
performed in Oslo, Norway, and compares results from three different datasets: two from 
survey methods and one from wastewater-based epidemiology. The second study 
analysed the temporal and spatial trends of cocaine use in Italy through wastewater-based 
epidemiology and compares the results with those obtained from local and national 
epidemiological surveys undertaken during the same period.
I Conclusions
For wastewater-based epidemiology to produce reliable estimates of illicit drug use and to 
inform the development of novel applications, the most urgent future research needs are 
as follows: (1) to improve the methodology by checking and reducing uncertainty factors 
for each single step; (2) to improve the comparability of results produced by different 
researchers or studies by adopting a common protocol of action, which will include ethical 
standards; and (3) to develop methods to integrate wastewater analysis with established 
methods of drug epidemiology.
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I Introduction
Sara Castiglioni
I Background to wastewater-based epidemiology
In modern society, humans are directly or indirectly exposed to a great variety of 
chemicals. Most of the chemicals that enter our body through the food or drink we 
consume or by other means such as smoking are excreted unchanged or as a mixture of 
metabolites in our urine and faeces, and ultimately end up in the sewer network. The 
concept of ‘wastewater analysis’ originates from research on monitoring the environmental 
pollution caused by pharmaceutical products and, in particular, from studies on the 
contamination of surface and sewage water caused by the excretion of therapeutic drugs 
by humans (Daughton, 2001).
The chemical analysis of wastewater was suggested for the first time as a ‘new non-
intrusive tool’ to evaluate the use of illicit drugs and misused therapeutic drugs within a 
community in 2001 (Daughton, 2001). It involves sampling a source of wastewater, such 
as the sewage influent to a wastewater treatment plant. This allows scientists to estimate 
the quantity of drugs consumed by a community by measuring the levels of illicit drugs and 
their metabolites excreted in urine (Zuccato et al., 2008).
Some studies in the early 2000s showed that the concentrations of misused 
pharmaceuticals in the environment were higher than expected (e.g. Calamari et al., 2003), 
indicating that the monitoring of these substances in the environment could reflect their 
pattern of use in the population. The occurrence of amphetamines in treated wastewater 
was studied for the first time in 2004 in the United States (Jones-Lepp et al., 2004). In 
2005, Zuccato and co-workers measured cocaine and its metabolites in raw wastewater 
samples, and, for the first time, used these data to back-calculate the consumption of 
cocaine by the population (Zuccato et al., 2005). This approach was called ‘sewage 
epidemiology’ or ‘wastewater-based epidemiology’ and was soon extended to the other 
main illicit drugs.
In recent years, wastewater-based epidemiology has been applied worldwide by several 
research groups at local and national scales, demonstrating the potential of the approach 
for quantifying illicit drug use at community level (Zuccato et al., 2008; Castiglioni et al., 
2011; van Nuijs et al., 2011). In 2010, a Europe-wide network (the Sewage Analysis CORe 
group Europe – SCORE group) was set up with the aim of standardising the approaches 
used for wastewater analysis and coordinating international studies through the 
establishment of a common protocol of action (see Chapter 1). The work of the SCORE 
collaboration continues through the Earth System Science and Environmental 
Management (ESSEM) European Cooperation in Science and Technology (COST) Action 
ES1307 ‘Sewage biomarker analysis for community health assessment’ (1).
From the outset, the European Monitoring Agency for Drugs and Drug Addiction 
(EMCDDA) showed a strong interest in exploring the potential of wastewater analysis to 
complement and extend the existing epidemiological tools. Wastewater analysis has some 
clear advantages over other approaches, as it is not subject to response and non-response 
bias and, as users are often unaware of the actual substances in the mix of drugs that they 
take, can better identify the true spectrum of drugs being consumed. The wastewater 
method is a flexible tool, as experiments can be designed to study drug use in a specific 
area or to compare the use between different areas during defined periods of the year or 
(1)  Information on COST action ES1307 is available at www.cost.eu/domains_actions/essem/Actions/ES1307. 
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over successive years. As a result, the tool has the potential to provide timely information 
in short timeframes on geographical and temporal trends, including changing trends in 
particular locations, or during special events or public holidays.
Wastewater analysis offers an interesting and complementary data source for monitoring 
the quantities of illicit drugs used at population level, but it also has several limitations 
which should be carefully evaluated. Wastewater analysis cannot provide information on 
prevalence and frequency of use, route of administration, the main classes of users or the 
purity of the drugs. Additional challenges may arise as a result of uncertainties associated 
with the sampling of wastewater, the behaviour of the selected biomarkers in sewage, the 
reliability of interlaboratory analytical measurements, the different back-calculation 
methods used and the different approaches used to estimate the size of the population 
being tested (Thomas et al., 2012; Castiglioni et al., 2013). Furthermore, translating the 
total consumed amounts into the corresponding number of average doses is complicated 
as drugs can be taken by different routes and in amounts that vary widely, and purity levels 
fluctuate (Zuccato et al., 2008). Wastewater analysis is therefore proposed as a 
complement to, rather than as a replacement for, established monitoring tools.
This novel method of investigation has a strong multidisciplinary character, involving both 
environmental and social sciences. Until now, the main limitation was bringing together, 
and stimulating discussion and collaborations between, people working in different 
disciplines, namely chemists, water system engineers, pharmacologists and 
epidemiologists. In this framework, the first steps were taken by the EMCDDA, which 
organised, in 2013, in collaboration with the SCORE network and the EU-funded 7th 
framework programme Marie Curie Initial Training Network SEWPROF project, the first 
multidisciplinary conference, ‘Testing the waters’, on the detection of illicit drugs in 
wastewater. By uniting diverse disciplines, the conference created for the first time a forum 
for the discussion of future opportunities for combining wastewater analysis and drug 
epidemiology. 
A second ‘Testing the waters’ conference took place on 11–15 October 2015. The 
conference brought together scientists and stakeholders from all involved disciplines to 
integrate results and contribute to the solution of a complex, societal problem such as 
drug use. The main aims of the conference were (1) to present monitoring studies 
integrating results from wastewater analysis and other epidemiological data; (2) to discuss 
scientific advances in individual disciplines in order to refine components of wastewater-
based drug epidemiology; (3) to present improved methodologies for back-calculation of 
drug use and advances in analytical chemistry; (4) to discuss legal and ethical aspects of 
the approach; (5) to contribute to filling current gaps and provide guidance on future 
applications. 
Research in this field is progressing very fast, with an increasing number of environmental 
chemists and engineers working together in a European network, in close collaboration 
with other groups in the United States, Canada and Australia, and with drug use 
epidemiologists, pharmacologists and addiction and prevention institutions in Europe, the 
United States and Australia. As a consequence, the number of publications available in 
this field is increasing and new knowledge and research advances are rapidly being added 
to the current knowledge. The rapid developments since the release of the EMCDDA’s 
seminal work on wastewater epidemiology, the 2008 Insights ‘Assessing illicit drugs in 
wastewater’, have left that publication increasingly obsolete and in need of replacement by 
a publication that presents the latest findings in this research field.
This report presents the state of the art regarding wastewater-based epidemiology, 
including most of the findings from the ‘Testing the Waters’ conferences, and the results 
obtained from the initial years of activity of the SCORE network in Europe and from other 
Introduction
13
studies performed worldwide. Since 2008, when the approach was still in its infancy and 
when the EMCDDA published the first Insights report on this topic, great advances have 
been made in this research field. This is mainly as a result of the increasing number of 
groups that implement wastewater analysis worldwide, providing drug use estimates in a 
number of different countries, and because of the numerous studies focused on 
addressing critical issues and, therefore, improving the reliability of the approach.
I Overview of this publication
Chapter 1 provides a detailed description of the wastewater-based epidemiology 
approach, including a description of the best-practice protocol that was recently 
established to produce comparable data. The chapter also describes the most up-to-date 
procedures available for estimating illicit drug use within a community and summarises 
contributions regarding the optimisation of sampling and monitoring, chemical analyses 
and quality control, enantiomeric profiling of illicit drugs, stability of drug residues in urban 
wastewater and population size estimation.
Chapter 2 focuses on the main requirements for wastewater drug biomarkers, namely the 
specific substances selected as target drug residues in wastewater and used for back-
calculating drug consumption values. A number of criteria that are essential for choosing 
proper target drug residues are presented. Back-calculation relies on specific correction 
factors which take into account mainly the urinary metabolism of a substance; 
unfortunately, human pharmacokinetic data are limited for most of the main illicit drugs, 
and, in general, the available studies were not performed recently and were based on a 
small number of participants. The further research needs are discussed and a critical 
overview of the current procedures used for back-calculating drug consumption is 
provided, giving some guidelines with regard to choosing or developing novel correction 
factors.
Chapter 3 presents an overview of the application of wastewater-based epidemiology 
worldwide. The results from four successive Europe-wide monitoring campaigns, 
coordinated by the SCORE network and performed in 2011 and each year since then, are 
presented in the first part of the chapter. The second part of the chapter reports a 
comprehensive summary of results obtained in the United States, Canada, Australia and 
Asia, and provides a comparison of all the available data.
Chapter 4, by Malcolm Reid and Kevin Thomas of the Norwegian Institute for Water 
Research, introduces a novel application for wastewater-based epidemiology, namely to 
detect the use of new psychoactive substances. This could be particularly useful because 
these substances constitute a heterogeneous group of synthetic products that are largely 
interchangeable, and very little is known about their use and prevalence. Conceptual 
approaches for dealing with new psychoactive substances using biomarkers in wastewater 
are discussed and an updated overview of the available applications is presented.
Chapter 5 is a collaboration between the Mario Negri Institute, Italy, and the Norwegian 
Institute for Water Research; it reports the first two case studies designed to integrate 
wastewater-based epidemiology with conventional approaches for estimating drug use 
within a community. In Italy, a nationwide monitoring campaign was performed in 17 cities 
to estimate drug use through wastewater analysis, and the results were compared with 
those obtained from an epidemiological survey conducted in the general population in the 
same period. In Norway, the results obtained from using three different methods for 
estimating the level of cocaine use in the general population were compared. The 
comparison applies to a set of regional-scale sample survey questionnaires, a 
representative sample survey on drug use among drivers and an analysis of the quantity of 
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cocaine-related metabolites in wastewater. These studies emphasise the challenges and 
opportunities for future studies that aim to bring together wastewater analysis and drug 
epidemiology.
Chapter 6 summarises the main findings from Chapters 1 to 5, and formulates the future 
research directions and final remarks.
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I A stepwise approach
The wastewater-based epidemiology approach relies on 
the principle that traces of almost everything we consume 
are excreted, unchanged or as a mixture of metabolites, in 
urine and faeces, and ultimately end up in the sewer 
network. Thus, measuring target drug metabolic residues 
in raw wastewater allows the identification of the use of 
specific substances by a population. To date, the most 
popular application of this approach is for the estimation 
of illicit drug use in a community.
The method consists of several consecutive steps that 
allow researchers to identify and quantify target 
metabolic residues of illicit drugs in raw wastewater and 
back-calculate the amount of the corresponding illicit 
drugs that would have been consumed by the population 
served by the wastewater treatment plant. The general 
scheme for this approach is outlined in Figure 1.1. First, 
representative composite samples of raw wastewater 
are collected and analysed for the selected substances. 
The back-calculation of drug consumption is performed 
by (1) calculating the daily sewer loads of target residues 
(g/day) by multiplying the concentrations of the 
measured target residues (ng/l) by the daily flow rates of 
sewage (m3/day); (2) estimating the total consumption 
by applying a specific correction factor, which takes into 
account the average excretion rate of a given drug 
residue and the molecular mass ratio of the parent drug 
to its metabolite (Zuccato et al., 2008; van Nuijs et al., 
2011); (3) normalising consumption by dividing daily 
values by the number of people in order to facilitate 
comparison among cities (mg/day/1 000 population); 
and (4) assuming a mean dose to obtain a value in 
doses/day/1 000 population.
Between 2005 and 2010, an increasing number of 
research groups applied their own methods to assess 
the use of illicit drugs, at local and national levels, in 
several countries, demonstrating the potential of the 
approach for quantifying illicit drug use at a community 
level. Unfortunately, it is difficult to compare the results 
of these early studies because of the lack of common 
procedures with regard to the approaches used for 
sampling the wastewater and for the back-calculation of 
illicit drug consumption. Therefore, it was essential to 
establish some practical guidelines to ensure the proper 
application of the wastewater-based epidemiology 
approach. In 2010, a group of researchers working in this 
field established the Sewage Analysis CORe group 
Europe (SCORE) network to harmonise the approach 
and to coordinate international studies through the 
establishment of a common protocol of action. The first 
activity organised by the SCORE group was a Europe-
wide investigation, performed in 2011 in 19 European 
cities, which allowed the first ever wastewater study on 
the regional differences in illicit drug use in Europe 
(Thomas et al., 2012). This study also included the first 
intercalibration exercise for the evaluation of the quality 
of the analytical data and allowed a comprehensive 
characterisation of the major uncertainties of the 
approach (Castiglioni et al., 2013).
This chapter first presents an overview of the most 
relevant areas of uncertainty related to wastewater-
based epidemiology. This is followed by an overview of 
the wastewater-based epidemiology stepwise approach, 
describing the SCORE best-practice protocol, which 
represents the most comprehensive and up-to-date 
information available on this topic. The latest research on 
sampling, chemical analyses, stability of target residues 
CHAPTER 1
Estimating community drug use 
through wastewater-based 
epidemiology
Sara Castiglioni, Lubertus Bijlsma, Adrian Covaci, Erik Emke, 
Christopher Harman, Félix Hernández, Barbara Kasprzyk-Hordern, 
Christoph Ort, Alexander L. N. van Nuijs, Pim de Voogt and 
Ettore Zuccato
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some research involving annual monitoring campaigns 
that include specific quality control tests is being 
performed in order to evaluate the reliability of sampling, 
sample storage and chemical analysis (Ort et al., 2014b).
Lai et al. (2011) assessed, for the first time, the 
uncertainties associated with sampling, through the 
optimisation of the sampling method, and with back-
calculation of the per-capita drug consumption, through 
a refined estimation of the number of people 
contributing to the wastewater. The uncertainties related 
to the sampling and chemical analysis of cocaine and its 
main metabolite benzoylecgonine were also assessed 
(Mathieu et al., 2011).
More recently, data collected from the first Europe-wide 
monitoring study (Thomas et al., 2012) and from other 
available literature were used to comprehensively 
address the uncertainty associated with all of the steps 
of the wastewater-based epidemiology approach 
(Castiglioni et al., 2013).
I Sampling of raw wastewater
Collecting representative composite samples of 
untreated wastewater is essential if the results of 
chemical analysis of wastewater are to give reliable 
figures for use in wastewater epidemiology, as 
demonstrated by Ort et al. (2010a). To improve the 
quality of the data, the sampling protocols were 
evaluated by analysing information collected using 
standardised questionnaires from all wastewater 
treatment plants involved in the first Europe-wide study. 
Data on sampling set-up (particularly sampling mode 
and frequency) and on catchment characteristics were 
gathered and the biases related to each sampling mode 
were evaluated. Based on these analyses and the expert 
judgement of a group of sewage engineers, some 
best-practice requirements were proposed, with the aim 
of greatly reducing sampling artefacts — which can 
range from ‘non-significant’ to ‘100 % or more’ resulting 
in overinterpretation of measured data — and 
minimising the uncertainty related to sample collection 
(< 10 %) (Castiglioni et al., 2013).
I Biomarker analysis
Laboratories performing chemical analysis of 
wastewater typically use their own in-house analytical 
methods. Despite the application of properly validated 
procedures, the employment of different analytical 
methods can produce results that are affected by bias, 
thus making the comparison of results difficult. Because 
in wastewater and population size estimation is also 
discussed. In addition, new analytical techniques, such 
as the analysis of enantiomers of chiral compounds, 
which allows the amounts of drugs consumed to be 
distinguished from the amounts discharged in urban 
wastewater, are described.
I Areas of uncertainty
The areas of uncertainty related to the wastewater-
based epidemiology approach were identified soon after 
its first applications (Zuccato et al., 2008), and some of 
these have already been mentioned in a previous 
EMCDDA publication (EMCDDA, 2008). These 
uncertainties are mostly associated with the main steps 
used to estimate community drug consumption through 
wastewater analysis (see Figure 1.1), namely sampling, 
chemical analysis, the stability of drug biomarkers in 
wastewater, the back-calculation of drug use and the 
estimation of the population size in a catchment area. 
Several efforts have been made in recent years to 
address these uncertainty factors in order to improve 
the reliability of the method. Nevertheless, the need to 
improve the comparability of data is still a priority, and 
FIGURE 1.1
The main consecutive steps of the wastewater analysis 
approach and the data required for each step 
Collection of raw wastewater samples
Normalisation of drug use to a dened population 
(mg/day/1 000 population)
Doses of drugs used in a population 
(doses/day/1 000 population)
Calculation of the daily sewer loads of target residues (g/day)
Concentration (ng/l) of each target residue in wastewater
Chemical analysis
Concentration × ow rate
Human excretion of target 
residues
Back-calculation of drugs consumption (g/day) 
Population estimates
Mean dose
NB: Modified from Castiglioni et al., 2014.
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degree of uncertainty that may arise from the 
biotransformation of a substance in a sewer and during 
sample handling.
I Back-calculation of drug use
There is also uncertainty associated with the correction 
factors used for back-calculating drug use from the 
levels of target residues. Normally, the correction factors 
are developed using the average excretion percentages 
of a target residue (Zuccato et al., 2008), which are 
obtained from a limited number of studies based on a 
very small sample of healthy volunteers. Moreover, 
excretion can vary according to the route of 
administration and the frequency of use of a substance. 
In order to reduce the uncertainty related to these 
variable factors, a systematic review of all 
pharmacokinetic data available for a substance was 
recently performed for cocaine, as a case study 
(Castiglioni et al., 2013). In this study, after sample 
collection, the excretion percentage of benzoylecgonine, 
which is the metabolite selected for estimating cocaine 
use, was weighted by the number of subjects involved in 
the pharmacokinetic studies and by the frequency of use 
of different routes of administration. This approach 
reduced the variability of the average benzoylecgonine 
excretion rate, from 42 %, before the refinement of data, 
to 26 % (Castiglioni et al., 2013), thus allowing 
refinement of the correction factor used to back-
calculate cocaine consumption. Similar results were 
obtained by using the Monte Carlo simulation approach 
in order to consider back-calculation of cocaine use in a 
formal statistical framework (Jones et al., 2014).
I Estimation of population size
If a comparison between different geographical areas is 
desired, drug estimates should be normalised to 
population size and, therefore, some measure of 
population size is needed. This is not an easy task, and a 
high degree of variability can be introduced in these 
calculations, as recently demonstrated during the 
analysis of data collected in 19 European cities 
(Castiglioni et al., 2013). Several methods based on 
measuring hydrochemical parameters in wastewater and 
collecting census data are currently used to estimate the 
population using a given sewer network. Additional 
methods, currently under development, use specific 
substances, such as creatinine, cotinine, 
pharmaceuticals, coprostanol and hormones, as 
anthropogenic markers in order to estimate population 
size and reduce associated uncertainties (see 
‘Estimation of population size’, page 28 for details).
of the prohibitive costs of additional analytical materials 
and instruments, it is not possible to ask researchers to 
change their in-house methods and adopt the same 
technique or the same equipment as other laboratories; 
however, several common quality control criteria can be 
adopted to reduce the potential errors associated with 
sample manipulation and storage, and to ensure similar 
evaluations of method performance. For instance, the 
use of reference standards for each compound was 
proposed in order to compensate for matrix effects 
during analysis and some guidelines have been 
established to coordinate the estimation of realistic 
limits of quantification and a common procedure for 
confirming positive results has been adopted in 
accordance with international standards (UNIDO, 2009).
An interlaboratory study was organised during the first 
EU-wide campaign to provide information on the 
variability resulting from the analytical measurements 
made by each of the participating laboratories. Two vials 
containing known concentrations of the selected 
analytes in methanol were prepared by one group and 
sent blind to each participating laboratory. Each 
laboratory was asked to determine the analyte 
concentrations in each vial, by quantitatively analysing 
three independent replicates of each solution, and to 
report the mean value of the triplicate measurements. 
The analytical performance of the laboratories was 
evaluated by calculating the variability from the mean 
(z-scores) for each laboratory. This is an internationally 
accepted measure for evaluating the performance of an 
individual laboratory with regard to a group average and 
it was a useful tool for evaluating the results of this 
interlaboratory study (Castiglioni et al., 2013). During 
successive analytical campaigns, intercalibration studies 
were conducted by also sending real wastewater 
samples spiked with different amounts of the selected 
analytes blind to each participating laboratory.
I Biomarker stability
The stability of the illicit drugs and metabolites normally 
chosen for monitoring in wastewater has been evaluated 
in sewer systems and during sampling, storage and 
analysis of samples by collecting the available 
information from the literature. In this way, it was 
possible to identify the most stable compounds that can 
be safely used as target residues to estimate drug use 
(see ‘Target drug residues in wastewater’ in Chapter 2 
for detailed results). For instance, benzoylecgonine was 
found to be the most suitable metabolite for estimating 
cocaine use, because of its relatively high stability in 
sewer systems. This information is essential for choosing 
a proper target residue and eventually identifying the 
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conditions for sample handling during storage and 
analyses.
The established common protocol of action, which was 
tested during the first European study, was later adopted 
by two successive studies conducted in 2012, in 25 
cities, and 2013, in 43 cities (Ort et al., 2014b). The 
concerted effort to produce comparable results allowed 
the generation of the most useful wastewater-based 
information on illicit drug use in Europe to date, and the 
first ever quantitative measurements of illicit drug use in 
certain European countries.
I  Optimisation of sampling and monitoring: challenges and alternatives
The first step to estimate drug use through wastewater 
analysis is the collection of ‘representative samples’ that 
should contain the entire amount of a substance 
discharged daily into wastewater from a defined 
community. Proper procedures should be therefore 
adopted to collect such samples from untreated 
wastewater at the point of inflow to wastewater 
treatment plants. Deciding upon the intensity of the 
monitoring effort entails weighing up the costs and 
benefits of possible sampling and analytical regimes. In 
simple terms, if information is to be of use for 
policymaking, it will need to have a relatively low level of 
uncertainty. Achieving this may imply relatively intensive 
sampling and analytical efforts, which may be costly. In 
practice, this means that an optimum level of research 
I Best-practice protocol
Several efforts have been made in recent years to 
address the uncertainty factors mentioned above in 
order to improve the reliability of the entire method. 
Knowledge of the proper procedures that should be 
adopted when implementing wastewater-based 
epidemiology has greatly improved, and specific 
guidelines are available as a best-practice protocol. The 
main aims of establishing this best-practice protocol 
were (1) to produce homogeneous and comparable data 
at different sites and (2) to provide the most reliable 
estimates of drug use to complement existing 
epidemiological studies consistently.
In view of the enormous potential of the wastewater-
based epidemiology approach and its wide application 
by different research groups, it is now highly 
recommended that all groups working in this field follow 
a common procedure while implementing the approach.
The best-practice protocol consists of several guidelines 
that address sample collection, storage and chemical 
analyses (see Table 1.1 for a summary of the main 
points). The protocol was established and formally 
agreed at a meeting held at Dublin City University 
(Ireland) on 14 December 2010. Later, the protocol was 
revised and improved after new expertise was gained 
during the successive analytical campaigns conducted 
in Europe. During these campaigns, sewer engineers 
were involved in evaluating the influence of different 
sewer designs and sampling procedures on the data 
generated, and analytical chemists were involved in 
establishing common procedures for evaluating the 
quality of analytical results and identifying the best 
TABLE 1.1
Summary of the main procedures described by the best-practice protocol currently adopted by Europe-wide studies
Phase of the approach Agreed procedures
Sampling and sample handling Sampling point: wastewater treatment plant influent
Sample type: 24-hour flow-weighted composite
Sampling container: PET or glass container
Questionnaire: developed to collect information on sewer systems, sampling mode and 
additional parameters such as BOD, COD, N, P, flow data, type of sewage influent, 
temperature, pH 
Storage treatment during sampling During sampling: < 4 °C
After sampling — two possible options:
1. Process the sample for analysis within 12 hours
2. Freeze the samples immediately after collection
Chemical analysis — quality control Substances investigated: cocaine, benzoylecgonine, amphetamine, methamphetamine, MDMA 
(3,4-methylenedioxymethamphetamine), 11-nor-9-carboxy-delta-9-tetrahydrocannabinol 
(THC-COOH)
Internal quality control: use of labelled analytical standards for each compound
External quality control: analysis of methanol standards and influent samples as prepared by 
one laboratory
NB: BOD, biological oxygen demand; COD, chemical oxygen demand; N, nitrogen; P, phosphorus; PET, polyethylene terephthalate. The protocol is 
available at www.emcdda.europa.eu/waste-water-analysis.
CHAPTER 1 I Estimating community drug use through wastewater-based epidemiology
21
sampling uncertainty can be kept below 10 % (relative 
standard deviation, RSD; also known as the coefficient of 
variation) (Mathieu et al., 2011; Thomas et al., 2012; 
Castiglioni et al., 2013). Because of systematic diurnal 
variations of wastewater flows and drug loads (Brewer et 
al., 2012; Lai et al., 2013), samples need to be collected 
in a flow- or volume-proportional manner (Ort et al., 
2010a, b) to avoid incorrectly weighted samples and 
biased results. Furthermore, because of potential 
short-term fluctuations, it is recommended that 
sampling intervals do not exceed 5–10 minutes. This 
would result in approximately 100–200 individual 
samples being collected over a 24-hour period. However, 
it should be noted that all of these samples are pooled 
before analysis and, therefore, this high sampling 
frequency does not necessarily increase analytical 
effort. A questionnaire to aid the collection of details 
relevant to the estimation and minimisation of sampling 
uncertainty in wastewater-based epidemiology is 
provided in the supporting information of Castiglioni et 
al. (2013), and free open-source software can also be 
found at www.eawag.ch/spg.
I Estimating annual averages
The estimation of annual averages is a suitable approach 
for wastewater-based epidemiology, as the resulting 
annual estimates of drug consumption by a population 
can be compared with several existing established drug 
epidemiology datasets and indicators (e.g. the self-
reported annual prevalence of drug use among the 
general population and annual drug seizure incidences). 
Specific efforts are now being directed towards finding 
the best procedures for estimating annual averages, as 
these cannot be directly obtained by analysing a few 
samples but need to be determined from a sufficient 
number of 24-hour composite samples collected 
throughout a year. This sample number is highly 
dependent on weekly and seasonal variations — for 
which we have limited information — and the desired 
level of accuracy. To date, only five studies, summarised 
in Ort et al. (2014a), investigated daily loads of illicit 
drugs over a 1-month period or more. Figure 1.2 shows 
the observed variations of daily drug loads expressed as 
coefficients of variation (CV). For benzoylecgonine, 
which was measured in all studies, load variations 
decreased with increasing population size. For other 
substances, such expected decreases could not be 
confirmed for various reasons. The high variation in 
3,4-methylenedioxymethamphetamine (MDMA) loads 
was mainly attributed to the high consumption of this 
drug at weekends and the fairly low (or non-detectable) 
consumption on working days. The number of samples 
(n) required to stay below a certain level of uncertainty
effort must be found, the so-called fit-for-purpose 
uncertainty level (Ramsey and Thompson, 2007). 
However, without a good understanding of the cost–
benefit relations of drug policy, it is difficult to establish 
the optimum uncertainty level for wastewater-based 
epidemiology. 
It is worth noting that wastewater-based epidemiology 
can use the existing infrastructure and that, other than 
the logistics involved, samples can be obtained at almost 
no cost (Banta-Green and Field, 2011). As there have 
been no relevant changes related to the sampling 
techniques described in the previous EMCDDA Insights 
on wastewater (Rieckermann, 2008), the aim of this 
section is to elucidate the scientific advances made since 
2008 in order to answer the following three questions: 
1)  What level of uncertainty could be achieved with the
existing sampling equipment and the routinely
applied sampling modes and frequencies?
2)  Are there situations that require particular attention?
3)  Are there alternative sampling technologies that
could apply to raw wastewater?
I Fluctuations of illicit drugs in sewers
The statement that ‘almost everything that is worth 
analysing is actually or potentially heterogeneous’ 
(Thompson, 1999) also applies to illicit drugs in sewers. 
Targeted high-frequency sampling campaigns have 
revealed high temporal fluctuations in the 
concentrations of illicit drugs and pharmaceuticals. 
These fluctuations are caused by substances entering 
wastewater in toilet flushes or pump stations lifting and 
transporting wastewater from entire sub-catchments 
intermittently to wastewater treatment plants. 
Specifically tailored sampling proficiency tests have 
demonstrated that inadequate sampling modes (e.g. 
grab samples or time-proportional composite sampling) 
and frequencies (i.e. intervals longer than 1 hour) can 
lead to substantial sampling artefacts, which can result 
in both over- and underestimation of results. In these 
cases, sampling errors can be larger than errors 
associated with chemical analysis (Ort et al., 2010a, b).
I Collecting 24-hour composite samples
For various practical reasons, 24-hour composite 
samples of raw wastewater from the influent of 
wastewater treatment plants are normally collected (Ort, 
2014). Thus, daily samples are the unit for analysis. 
Studies focusing on relatively large catchment areas and 
frequently used substances have concluded that 
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proportional sampling at even higher frequencies (i.e. 
frequencies of 1 per minute to 1 per 5 minutes) than the 
sampling frequency required for influents to large 
wastewater treatment plants. This would be even more 
pronounced for effluent from individual premises, such as 
schools or prisons. Another challenge is the assessment 
of the accuracy of flow measurements (Rieckermann, 
2008). This can be partly resolved by estimating the 
population size used to calculate population-normalised 
drug loads from wastewater parameters (Lai et al., 2011; 
O’Brien et al., 2014) (see also Estimation of population 
size, page 28). An alternative to active sampling 
technology is passive sampling. This involves the 
placement of a device (passive sampler) in the 
wastewater, where it accumulates chemicals through 
diffusive processes over time. Such technologies offer 
practical and economical advantages for gathering 
long-term, or geographically broad, data. For example, 
they have been used to estimate drug use in Oslo, 
Norway, for a 1-year period (Harman et al., 2011). It should 
be noted that there are several challenges involved with 
applying these techniques, including those associated 
with calibration and quantification, knowledge of kinetics, 
and the correction for different exposure scenarios 
(Harman et al., 2012).
The sampling procedures normally used in wastewater-
based epidemiology are sufficiently robust and reliable, 
(U) can be calculated by n = (CV/U)2. This means that 
site- and substance-specific coefficients of variation 
need to be calculated, which is a laborious task. Based 
on the limited data available to date, it seems that a 
coefficient of variation of 75 % is exceeded in only rare 
cases and, therefore, this could be considered a 
reasonable value. For certain substances, coefficients of 
variation can be substantially lower than this, implying 
that, for such substances, a smaller number of samples 
is required for the same level of accuracy. However, most 
samples are analysed for multiple substances and, 
therefore, the substance with the highest coefficient of 
variation will dictate the number of samples required. If 
the uncertainty of an annual mean does not exceed 
20 %, 14 samples randomly distributed over a year would 
be required (or for U = 10 %, 56 samples would be 
required).
I Challenges and alternatives
Future wastewater-based epidemiology may require 
sampling from small wastewater treatment plants, but 
these are often not equipped with sampling devices for 
the collection of raw influent wastewater. Furthermore, 
the concentrations of illicit drugs in wastewater and flows 
from small catchment areas can be subject to much 
higher fluctuations, which would require flow- or volume-
FIGURE 1.2
Variability of daily drug loads expressed as coefficients of variation (CV, standard deviation/mean)  
for five long-term studies
NB: Population sizes (P) and the number of subsequent monitoring days (d) for the five studies were as follows:   
  
  
  
  
 
P = 7 160, d = 1 369; 
  
  
  
  
  
 
P = 278 000, 
d = 311; 
  
  
  
  
  
 
P = 557 000, d = 28; 
  
  
  
  
  
 
P = 1.1 million, d = 239; 
  
  
  
  
  
 
P = 1.3 million, d = 28 and d = 35 (references and details in Ort et al., 2014a). EDDP, 
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; MDMA, 3,4-methylenedioxymethamphetamine.
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sensitive quantification and reliable identification. 
Hence, detection technologies should be both 
sufficiently specific and sensitive.
Modern analytical chemistry offers the solution to this 
challenging task. The use of advanced analytical 
techniques and the expertise of analysts are essential for 
obtaining accurate data with regard to drug residues in 
wastewater at trace levels (ng/l or parts per trillion) 
(Castiglioni et al., 2008; Postigo et al., 2008b). The 
medium-high polarity and low volatility of these 
compounds makes liquid chromatography coupled to 
mass spectrometry the technique of choice, particularly 
when using tandem mass spectrometry (Castiglioni et al., 
2013). Liquid chromatography–tandem mass 
spectrometry allows the simultaneous quantification and 
identification of the target compounds in complex 
matrices, thanks to its excellent sensitivity and selectivity. 
In the process, the substances are ionised and 
fragmented and are subsequently detected by monitoring 
for specific ion mass-to-charge ratios (m/z) for each 
compound. Typically, two transitions are acquired by 
selecting the precursor ions and the fragmented ions 
characteristic of the compound under study: one of these 
transitions, usually the most intense, is used for 
quantification (Q), and the other is used for confirmation 
(q). As an example, Figure 1.3 illustrates the detection and 
identification of cocaine and its main metabolite 
benzoylecgonine on the basis of two transitions (Q and q) 
acquired for each compound. For cocaine, the fragments 
with mass-to-charge ratios of 182 and 82, from the 
precursor ion with a mass-to-charge ratio of 304, were 
selected (Figure 1.3, left panel), and for benzoylecgonine, 
the fragments with mass-to-charge ratios of 168 and 82, 
from the precursor ion with a mass-to-charge ratio of 290, 
were used (Figure 1.3, right panel). By considering the 
except in settings where the target residues’ dynamics 
are extraordinarily high because of (1) a small absolute 
number of wastewater pulses containing the substances 
of interest (i.e. searching for ‘a needle in a haystack’) and 
(2) sampling locations close to the source. The latter is 
the case for effluent from individual premises or influents 
to small wastewater treatment plants. This is because 
toilet flushes are not attenuated by dispersion effects to 
the same extent over short distances as they are over 
longer distances: a toilet flush may extend over only a 
couple of seconds directly outside a house, depending 
on the sanitary installations and hydraulic conditions of 
the house connection. For high-prevalence drugs in large 
catchment areas, current best practice for sampling is 
expected to result in uncertainties that are smaller than 
or in the same range as other components of uncertainty 
(Castiglioni et al., 2013; Ort et al., 2014a).
I Chemical analysis and quality control
The estimation of community drug use through 
wastewater analysis requires accurate and sensitive 
quantification of illicit target drug residues (usually the 
unaltered drug, or the drug’s main metabolite, excreted 
in urine). Reliable data are the basis of subsequent 
calculations of drug loads in wastewater and drug 
consumption. The principal difficulties associated with 
the quantitative analysis of illicit drugs relate to their very 
low concentrations in combination with the complexity 
and unknown composition of wastewater. The 
concentrations of illicit drugs in wastewater are generally 
around a thousand-fold lower than in human biological 
fluids. Furthermore, the presence of a large number of 
other substances in the sample matrix may hamper 
FIGURE 1.3
Identification and quantification of cocaine (382 ng/l) and its major metabolite benzoylecgonine (931 ng/l) 
in wastewater by liquid chromatography coupled to tandem mass spectrometry
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and, therefore, this technique is limited to substances for 
which the method has been developed. Consequently, 
compounds other than the target compounds may be 
ignored in the analyses. High-resolution mass 
spectrometry transcends this limitation and shows strong 
potential for target and non-target screening. Another 
important possible use of this technique is for the 
investigation of the transformation products that can form 
in water. Liquid chromatography–high-resolution mass 
spectrometry has been limited to mainly qualitative 
screening (i.e. the detection and identification of 
compounds); however, recent improvements have also 
allowed its use for accurate quantification (Gonzalez-
Marino et al., 2012; Bijlsma et al., 2013).
Any analytical methodology should comply with strict 
quality requirements in order to generate reliable data. 
Quantitative method validation is obviously required, but 
the application of updated criteria based on the acquisition 
of several transitions, considering their specificity, or based 
on mass accuracy measurement is also necessary. 
Furthermore, the analysis of internal quality controls in 
each sample sequence ensures quality and tests for daily 
variations. However, another key aspect of the analytical 
methodologies used for wastewater-based epidemiology is 
that they generate data that are comparable among 
different laboratories. Therefore, the performance of 
interlaboratory exercises, in which the same sample is 
analysed by all participants, is necessary. The results 
obtained by such analyses provide an indication of the 
accuracy and performance of each laboratory, and the 
presence (or absence) of systematic errors.
Until now, most research in this field has been aimed at 
estimating the use level of established illicit drugs such 
as amphetamine, cannabis, cocaine, MDMA and 
methamphetamine. However, the advanced analytical 
techniques now available allow the presence of other 
compounds in wastewater, such as new psychoactive 
substances, which regularly appear on the market (Reid 
et al., 2014; van Nuijs et al., 2014; Chapter 4 of this 
Insight), to be investigated. In this regard, non-target 
high-resolution mass spectrometry is especially 
attractive, because of the lack of reference standards in 
many cases for new psychoactive substances, and the 
lack of available information on the metabolism of these 
substances (Ibáñez et al., 2014).
I Enantiomeric profiling of illicit drugs
When the presence of illicit drugs in wastewater is 
monitored regularly using a frequent sampling protocol, a 
baseline for daily drug loads resulting from consumption 
peak area of the quantitative transition (Q) in the sample 
and comparing it with that obtained for the reference 
standard, it is possible to calculate the concentration of 
each substance. The acquisition of two transitions, 
together with retention time data and the measurement of 
ion intensity ratios between recorded transitions in 
standards and samples, permits a reliable identification of 
the compound detected, even at very low concentrations 
(see quantification-to-confirmation-transition ratios in 
Figure 1.3 and the deviation values, which are within the 
permitted maximum tolerance level) (UNIDO, 2009).
Despite the strong potential of liquid chromatography–
tandem mass spectrometry for wastewater analysis, other 
compounds present in the sample may interfere and 
compete with the target residues during the ionisation 
process; this is known as the ‘matrix effect’. One of the key 
aspects of this analytical methodology that must be 
addressed, in order to ensure accurate quantification and 
reliable identification, is the removal, minimisation or 
correction of such matrix effects. Although the sensitivity 
of modern instruments is excellent, a sample treatment 
step is necessary to concentrate the analytes and clean 
up the sample. Solid-phase extraction is widely used for 
this sample treatment step. Other alternative sample 
treatment procedures, such as on-line solid-phase 
extraction (Postigo et al., 2008a) and large-volume 
injection (Chiaia et al., 2008; Berset et al., 2010), open up 
possibilities for fully automated analysis. In the near 
future, new and even more sensitive liquid 
chromatography–tandem mass spectrometry 
instruments may help to improve the performance of 
these methods, and will allow the extra dilution of sample 
extracts or reduce the need to concentrate the samples, 
thereby helping to minimise matrix effects.
Most of the reported methodologies use internal 
standards, which are added to the samples as 
surrogates (i.e. before sample treatment) for more 
accurate quantification. Reference standards, preferably 
an isotope-labelled analyte for each target compound, 
are commonly added to compensate for matrix effects 
and to ensure the satisfactory correction for analytical 
errors associated with sample manipulation and storage.
Nowadays, liquid chromatography–tandem mass 
spectrometry is widely recognised and accepted as an 
accurate method for the quantification of target drug 
residues in wastewater. However, high-resolution mass 
spectrometry provides new perspectives for this analytical 
field because of the powerful information provided by this 
technique (accurate-mass full-spectrum mass data). When 
using liquid chromatography–tandem mass spectrometry, 
identification and quantification are directed towards 
specific compounds that have previously been selected, 
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(Kasprzyk-Hordern and Baker, 2012b). The chemical 
synthesis of compounds with one asymmetric centre will 
generally lead to equal amounts of the two 
corresponding enantiomers (a racemic mixture) in the 
product synthesised (e.g. the synthesis of MDMA usually 
produces equal amounts of the S(+) and R(–) 
enantiomers). The ratio of the concentration of one 
enantiomer to the sum of the R(–) and S(+) forms, that is 
R(–):(R(–) + S(+)), can be defined as the enantiomeric 
fraction; therefore, a racemic mixture will have an 
enantiomeric fraction of 0.5. It should, however, be 
emphasised that certain illicit drugs are synthesised via 
stereoselective routes (subject to the availability of 
substrates). For example, more potent S(+)-
methamphetamine is usually synthesised in clandestine 
laboratories by the reduction of 1R,2S(–)-ephedrine or 
1S,2S(+)-pseudoephedrine (naturally produced by the 
ephedra plant) (Kasprzyk-Hordern and Baker, 2012b).
The human metabolism of a product containing a racemic 
mixture of enantiomers will change the enantiomeric ratio 
as a result of differences in the metabolic conversion 
rates of different enantiomers (Emke et al., 2014). For 
example, S(+)-amphetamine is metabolised preferentially 
over R(–)-amphetamine, leading to a relative enrichment 
of the R(–) enantiomer in urine (Kasprzyk-Hordern and 
Baker, 2012b). Furthermore, the enantiomeric ratio can be 
influenced by microbial activity during sewage water 
transport in the catchment area and also by active sludge 
in the sewage water treatment plant, leading to, for 
example, further enrichment of the R(–) enantiomers of 
amphetamine and MDMA (Kasprzyk-Hordern and Baker, 
2012a).
An example of enantiomeric profiling: analysing 
MDMA in wastewater
Many synthetic routes for producing MDMA start with 
piperonyl methyl ketone (PMK) and use either the 
in the corresponding community can be estimated. In 
some cases, however, aberrantly high loads may be 
observed in a sewer which could not possibly correspond 
to the actual level of drugs consumed by that specific 
community. These abnormally high loads may result from 
the direct disposal of unused drugs or production waste 
from, for example, illegal manufacturing facilities; these 
factors make the epidemiological estimation of 
community-wide drug use via wastewater analysis 
difficult and potentially unreliable. Therefore, it is of the 
utmost importance that new approaches are introduced 
to distinguish between drug loads in wastewater that 
result from consumption and those that result from the 
direct disposal of unused drugs (Emke et al., 2014). 
Enantiomeric profiling of drugs in wastewater by chiral 
chromatography coupled with mass spectrometry could 
be a viable option to solve these problems.
A chiral molecule usually has at least one chiral centre 
(e.g. an asymmetric carbon atom); as a result of this, it 
shows optical activity. Chiral molecules exist as two 
enantiomers (if only one chiral centre is present), which 
are non-superimposable mirror images of each other 
(Figure 1.4). Many of the popular psychoactive illicit and 
new drugs (e.g. cocaine, amphetamines and cathinones) 
contain one or more asymmetric carbon atoms (Emke et 
al., 2014). Enantiomers of the same compound exhibit 
the same physicochemical properties, but they differ in 
their biological properties: in their distribution in the 
body, their metabolism and their excretion from the 
body, as one enantiomer will be favoured over the other. 
This results from the fact that enantiomers react 
stereoselectively, for example with enzymes, in 
biological systems (Kasprzyk-Hordern, 2010). Two 
enantiomers of the same drug can also exhibit different 
potencies; for example, S(+)-MDMA is known to be more 
amphetamine-like than the R(–) enantiomer of this drug, 
R(–)-MDMA is known to be more hallucinogenic than the 
S(+) enantiomer, and S(+)-amphetamine has a two-fold 
higher stimulant activity than R(–)-amphetamine 
FIGURE 1.4
Enantiomers of 3,4-methylenedioxymethamphetamine (MDMA)
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campaign in 2010 (the average load in 2011 was 
20-fold higher than the average load in 2010) (Bijlsma 
et al., 2012). To determine whether or not the MDMA in 
the wastewater had been consumed by humans, 
enantiomeric profiling of these sewage water samples 
was undertaken. It was shown (Figure 1.5) that the 
average enantiomeric fraction of MDMA was 0.54 for 
the 2011 sampling week. This indicates that the MDMA 
quantified in wastewater during this sampling week 
was a racemic mixture, which indicates that it resulted 
from the direct disposal of MDMA into the sewage 
system and therefore explains the high loads of MDMA 
found in Utrecht wastewater during the 2011 sampling 
week. The relatively slow decrease in the MDMA load 
after the assumed disposal (red line in Figure 1.5) can 
be explained by the characteristics of the wastewater 
treatment plant in Utrecht, in which effluent is partly 
recirculated (one-third on a dry day) into the influent. 
This direct disposal could have been the result of a 
police raid on an illegal production facility that took 
place 2 days before the monitoring had started: the 
police estimated that 30 kg of raw MDMA or tablets had 
been disposed of in response to the raid. In contrast, 
the samples from 2010 (green line in Figure 1.5) 
showed an average enantiomeric fraction of 
0.65, which corresponds to excretion 
profiles in urine after MDMA consumption 
(Emke et al., 2014).
Until now, it has been difficult to determine if mass loads 
of studied drugs originated from consumption, the 
disposal of unused drugs or production waste. This 
uncertainty in the route by which drugs enter wastewater 
should not be underestimated when applying 
wastewater-based epidemiology. In this regard, 
enantiomeric profiling of wastewater is a new and very 
promising approach to solving this problem.
Leuckart route or various reductive amination reactions 
(Renton et al., 1993). All of these methods produce 
racemic MDMA. S(+)-MDMA is, however, metabolised in 
preference to R(−)-MDMA, which leads to the relative 
enrichment of the MDMA R(−)-enantiomer and the 
preferential formation of S(+)-3,4-methylenedioxy- 
amphetamine (MDA) (Moore et al., 1996). Moore et al. 
(1996) also observed that in both bile and urine, which 
are the primary routes of MDMA excretion in humans, 
R(−)-MDMA was present at a higher concentration than 
S(+)-MDMA (an enantiomeric fraction of 0.57, based on 
autopsy findings). These fluids also contained a two-fold 
higher concentration of S(+)-MDA than the R(−)-
enantiomer of MDA (enantiomeric fraction of 0.37, 
based on autopsy findings). This information is very 
important with regard to the verification of whether 
residues of a chiral drug present in wastewater result 
from its actual consumption (i.e. if the enantiomeric 
fraction is not equal to 0.5) or from its direct disposal 
(i.e. if the enantiomeric fraction is 0.5). As MDMA does 
not currently have medical applications, its presence in 
biological specimens is believed to result from illicit use 
(Emke et al., 2014). Indeed, Kasprzyk-Hordern and Baker 
(2012b) reported, in the first study of its kind, that 
wastewater was enriched with the R(–)-MDMA 
enantiomer because of the preferential metabolism of 
S(+)-MDMA in humans. Furthermore, the majority of 
MDA identified was the S(+) enantiomer, which 
suggests that its presence is associated with MDMA 
consumption and subsequent metabolism into S(+)-
MDA and not intentional MDA consumption (if the latter 
were true, there would be more of the R(–)-enantiomer 
of MDA in wastewater).
In 2011, anomalously high mass loads of MDMA were 
observed in wastewater from the city of Utrecht in the 
Netherlands. These loads deviated greatly from the 
loads observed during the previous monitoring 
FIGURE 1.5
MDMA loads detected in samples from the wastewater treatment plant of Utrecht, the Netherlands, collected in 
1-week sampling periods in 2010 and 2011, and their corresponding enantiomeric fractions
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assess the stability of cocaine and its major 
metabolites, benzoylecgonine and ecgonine methyl 
ester, in wastewater. Benzoylecgonine was found to be 
the most stable cocaine residue in wastewater, with 
less than 20 % biotransformation after 24 hours, at pH 
7.5 and room temperature (Table 1.2). The observed 
increase in benzoylecgonine concentrations over time 
was due to a partial degradation (hydrolysis) of cocaine 
to benzoylecgonine, a process that was also observed 
in blood and urine. The two other residues under 
investigation, cocaine and ecgonine methyl ester, were 
significantly less stable in wastewater than 
benzoylecgonine, with losses of up to 60 % and 40 %, 
respectively, after 12 hours, at pH 7.5 and room 
temperature. However, some inconsistencies in the 
degradation rates of these two compounds were 
observed among various studies, probably because of 
differences in the experimental set-ups, such as the 
sample matrix (i.e. differing characteristics of the 
wastewater used) and spiking concentrations. 
Experiments to assess the stability of 11-nor-9-
carboxy-delta-9-tetrahydrocannabinol (THC-COOH), 
the most abundant residue in wastewater resulting 
from cannabis use, demonstrated that this compound 
is stable under relevant conditions (24 hours, pH 7.5 
and 20 °C). By contrast, significant losses were 
observed, under these conditions, for the 
transformation product of heroin consumption, namely 
6-monoacetylmorphine.
I  Stability of drug residues in urban wastewater
The stability of drug residues in wastewater is a property 
that has to be evaluated with care, as it can lead to 
significant under- or overestimations when calculating 
drug use in wastewater-based epidemiology. Therefore, 
it is imperative that knowledge is gathered on the 
behaviour of the target drug residues in sewer systems 
(i.e. the in-sewer stability of drug residues from the place 
of excretion to the place of sample collection) and the 
stability of these compounds in the sample matrix during 
the collection and storage of wastewater.
The transformation of drug residues in wastewater 
from the place of excretion to the place of sample 
collection in the wastewater treatment plant (in-sewer 
biotransformation) has been assessed in a number of 
studies. In all of these studies (Table 1.2), the 
amphetamine-like stimulants under investigation were 
amphetamine, methamphetamine and MDMA, and 
these substances showed negligible transformation in 
wastewater after 12 hours (or even up to 24 hours) at 
room temperature. At the lower temperature of 4 °C, 
these amphetamine-like stimulants were stable for up 
to 3 days. These three compounds have also been 
found to be stable in urine at 37 °C for 3 days and 
longer. Experiments have also been performed to 
TABLE 1.2
Summary of experiments used to assess the stability of the main illicit drugs and several metabolites  
(percentage change after incubation)
Reference
Time 
(hours)
Temperature 
(°C)
pH Cocaine, %
Benzoylec-
gonine, %
Ecgonine, %
Amphet-
amine, %
Methamphet-
amine, %
MDMA, %
THC-
COOH, %
6-MAM, % 
Castiglioni et al., 
2006
72  4 7.5 –36 14 NA 5 0 1 –8 –14
Gonzalez-Marino 
et al., 2010
24  4 7.5  –7 7 NA 0 NA NA 2 NA
Bisceglia, 2010; 
Bisceglia and 
Lippa, 2014
12 23 7.4 –50 10–14 –40 –15 0 0 NA –15
Baker and 
Kasprzyk-
Hordern, 2011
12 19 7.4  –8 7 NA 47 8 1 NA –42
Castiglioni et al., 
2011
24  4 7.5 –25 20 –50 NA NA NA NA NA
van Nuijs et al., 
2012
12 20 7.5 –40 6 –20 3 2 3 NA –20
Plosz et al., 2013  7 21 7.4 –60 18 –29 NA NA NA NA NA
Thai et al., 2014 12 20 7.5 –20 14 NA NA 0 0 NA –25
Chen et al., 2013 24 20 7.0 –9 NA NA NA –5 1 NA –53
Senta et al., 
2014
24 20 7.5 –35 15 NA –5 –10 –10 0 –15
6-MAM, 6-monoacetylmorphine; MDMA, 3,4-methylenedioxymethamphetamine; NA, not applicable; THC-COOH, 11-nor-9-carboxy-delta-9-tetrahydro-
cannabinol.
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samplers are used, analytes are extracted from the 
wastewater in situ, which should overcome some of 
these stability issues. However, this assumption has yet 
to be tested.
In view of the above-mentioned findings, if the proper 
procedures are adopted, the degradation processes that 
occur during in-sewer transport, sampling and storage 
can be expected to make a negligible contribution to the 
total uncertainty of the results of wastewater-based 
epidemiology for several of the most commonly used 
illicit drugs.
I Estimation of population size
To compare results from different sites, it is essential to 
know the size of the population that contributes to the 
sampled wastewater (Figure 1.1). Different methods 
have been proposed for the collection of information on 
population size and fluctuations thereof. Because of the 
different kinds of potential bias related to each of these 
various methods, it is not recommended that only one 
particular method is relied upon. Currently, population 
size can be estimated by measuring different 
hydrochemical parameters, such as biological oxygen 
demand, chemical oxygen demand, and nitrogen and 
phosphorus levels, and by using specific loads for these 
parameters (i.e. per-capita loads from domestic activity) 
to calculate the number of people contributing to the 
sampled wastewater (Andreottola et al., 1994). Recently, 
Been and co-authors (2014) tested the possibility of 
normalising population size using ammonium levels, and 
their method appears to be able to detect fluctuations in 
the size of a population over long periods or during major 
events. Another option for estimating population size is 
to collect census data for the area under investigation. A 
comparison of the population estimates obtained from 
these different methods has been performed using data 
collected from 19 European cities and the variability was 
shown to range from 7 % to 55 % (RSD) (Castiglioni et 
al., 2013). The reliability of these estimates depends on 
factors that cannot easily be controlled, such as the 
composition of the sewage (e.g. industrial, domestic or 
mixed), which can influence the hydrochemical 
parameters, the reliability of census data, the quality of 
the measured flow data and the method used to 
calculate population equivalents. Moreover, in the case 
of large cities, the number of commuters should also be 
evaluated. Therefore, it is not deemed appropriate to use 
a mean value of the population estimates calculated 
using the different methods described because of the 
large amount of bias that could be introduced into the 
final calculations of drug use estimates. So far, the best 
Considering that typical in-sewer residence times are 
less than 10 hours, this means that transformation (or 
degradation) is generally lower than 10 % for 
amphetamine, methamphetamine, MDMA, 
benzoylecgonine and THC-COOH. In-sewer degradation 
will, therefore, have negligible influence on wastewater 
analysis results if these compounds are used in back-
calculations. However, if 6-monoacetylmorphine is used 
for back-calculation of heroin consumption, actual heroin 
use is likely to be underestimated because of the 
considerable losses of the residue due to in-sewer 
transformation.
Clearly, better designed and more sophisticated 
research in this area is necessary to assess other factors 
that could influence in-sewer losses and transformation, 
such as adsorption to solid matter, formation of biofilms 
and deconjugation processes. Moreover, most of these 
experiments have been conducted only in the laboratory, 
mimicking ‘real conditions’ for temperature and sewage 
composition. Only one modelling study addressing drug 
stability in wastewater has been conducted to date 
(Plosz et al., 2013); thus, it is important that in-sewer 
experiments are designed and additional modelling 
studies are performed to further investigate the in-sewer 
biotransformation of target residues and to confirm the 
current data.
In addition to assessing in-sewer transformation, it is 
important to evaluate the stability of drug residues in 
wastewater during sampling (typically 24-hour 
composite sampling) and sample storage. Upon 
collection, samples are typically cooled to 4 °C and 
stored at that temperature (Table 1.1). The experiments 
summarised in Table 1.2 demonstrate that cocaine, 
ecgonine methyl ester and 6-monoacetylmorphine are 
not stable at 4 °C and pH 7.5. In addition, the 
concentration of benzoylecgonine in composite samples 
could possibly increase by as much as 20 % over a 
24-hour period at 4 °C if cocaine is present. This would 
result in overestimations of cocaine use in wastewater-
based epidemiology. Acidification efficiently prevents 
the ‘formation’ of benzoylecgonine from cocaine during 
24-hour composite sampling. For the other investigated 
drug residues, bringing the samples to refrigerator 
temperatures is sufficient to prevent transformation. 
After sampling, drug residues need to be stable in 
wastewater until the actual analysis can be performed. 
The two most commonly applied strategies described in 
the literature are as follows: (1) samples are directly 
frozen (at −20 °C) after collection or (2) samples are 
processed using solid-phase extraction cartridges within 
12 hours of collection (Table 1.1). These conditions 
prevent the degradation of the drug residues in the 
collected wastewater. It should be noted that, if passive 
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interday excretion and correlation with census 
population data, were fully investigated for the first time 
by Chen et al. (2014). The results of this study suggest 
that cotinine and 5-hydroxyindoleacetic acid are the 
most suitable compounds (Chen et al., 2014).
Some years ago, the concentrations of the principal 
metabolites of nicotine, cotinine and trans-3′-
hydroxycotinine, were found to correlate with the 
population in the catchment areas of several Swiss 
lakes, and were proposed as anthropogenic markers 
(Buerge et al., 2008). These substances were recently 
measured in raw wastewater from eight wastewater 
treatment plants in Italy and were assessed for their 
potential to be population biomarkers. They were shown 
to have a defined urinary metabolism in humans, and to 
be easily detectable and stable in wastewater; thus, it 
was possible to back-calculate nicotine consumption 
using specific correction factors. The prevalences 
calculated through the analyses of these substances in 
wastewater were very similar to those obtained from 
epidemiological surveys (Castiglioni et al., 2015). Similar 
results were obtained by a study in Lisbon, Portugal, in 
which only cotinine was measured in three wastewater 
treatment plants and was used to back-calculate 
nicotine consumption; the results of this study were in 
line with the findings of a European survey (Lopes et al., 
2014). This suggests that the levels of nicotine 
metabolites measured in wastewater reflect the number 
of smokers within a population. Therefore, by considering 
this information and the average number of cigarettes 
smoked per day according to epidemiological surveys, it 
is possible to use nicotine metabolites to estimate the 
population size served by a wastewater treatment plant. 
Further investigations are now required to confirm these 
preliminary results.
To reduce and quantify the uncertainty of population 
estimates, it seems reasonable to combine multiple, 
unbiased indicators of population size measured in 
wastewater. One option — applying Bayesian inference 
— was recently developed by O’Brien et al. (2014). The 
results, based on multiple pharmaceuticals, were 
validated with the de facto population size, enumerated 
on census day through a georeferenced analysis (in 
Australia, both de facto and de jure population sizes are 
determined on census day). Therefore, no information on 
pharmaceutical sales was needed. This approach is able 
to produce accurate estimates of population sizes for 
large cities, while further research is needed to improve 
estimates for smaller populations. Most importantly, this 
approach provides a reliable indication of the 
uncertainty of the population estimate, implicitly 
including the spatiotemporal variability of indicators. This 
cannot be obtained in the same manner with other 
option available, even if not ideal, is to compile estimates 
based on different methods and to choose the most 
reliable one using the expert judgement of wastewater 
treatment plant personnel. This was the procedure 
adopted in several recent European monitoring 
campaigns (Thomas et al., 2012; Ort et al., 2014b).
An interesting possibility would be to find specific 
substances that, once measured in wastewater, could 
indicate unequivocally the number of people served by a 
wastewater treatment plant. Such substances would 
have to fulfil several requirements; for example, they 
would have to be excreted in urine in known amounts, be 
detectable and stable in wastewater, and originate from 
only human metabolism (see Chapter 2 for further 
details). Several potential candidates, such as creatinine, 
coprostanol, caffeine, pharmaceuticals, biocides and 
food additives, have been proposed for further 
investigation (Daughton, 2012), and some studies tested 
the viability of these substances as population 
biomarkers in the 2 years prior to the publication of this 
EMCDDA Insight.
Because of the relatively homogeneous spatiotemporal 
use of certain pharmaceuticals, measuring 
pharmaceutical loads was suggested as a means of 
estimating the number of people that contribute to 
sampled wastewater (Lai et al., 2011). Unfortunately, 
methodological challenges related to the availability of 
reliable prescription data on pharmaceuticals, data on 
actual consumption (which depends on patients’ 
compliance), data on excretion rates and the estimation 
of associated uncertainties remain. However, expanding 
this approach from single to multiple substances is 
considered very promising.
Creatinine was used as a qualitative biomarker to 
normalise the loads of several illicit and licit drugs, and 
this allowed the study of diurnal and between-day trends 
by taking into account changes in population (Brewer et 
al., 2012). Nevertheless, the stability of creatinine in 
such studies should be established, since there is 
evidence that the degradability of creatinine in sewer 
conditions can affect its potential for use as a biomarker 
and could, therefore, introduce further bias to the 
estimation of population size (Chen et al., 2014; Thai et 
al., 2014).
Seven substances, compising those already proposed 
(creatinine, cholesterol, coprostanol and cotinine) and 
three new compounds (cortisol, androstenedione and 
5-hydroxyindoleacetic acid), were screened as potential 
population biomarkers using five different criteria. These 
criteria, namely quantification methods, affinity to 
particulates, stability in wastewater, constancy of 
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communities (e.g. workplaces, schools, prisons, city 
districts and entertainment venues). The ethical 
concerns regarding such settings are mainly related to 
the possible identification or stigmatisation of a 
particular group. In the case of prisons and 
entertainment venues, risks are also related to the 
policies that authorities may apply in response to 
wastewater-based epidemiological findings, which may 
lead to a reduction of drug supply and demand that 
could adversely affect all occupants of such premises 
(Prichard et al., 2014). These risks could be prevented by 
introducing rigorous procedures into the study design to 
protect the anonymity of sample members and by not 
identifying the location of study sites. Moreover, 
particular care must be taken when sampling in small 
communities, as artefacts can easily occur because of 
the very limited number of people using illicit drugs and 
the specific design of small sewer systems. 
The two available studies that deal with ethical issues on 
wastewater-based epidemiology suggest that the 
development of ethics guidelines that retain the scientific 
rigour of the research while protecting the anonymity of 
smaller or disadvantaged populations, such as those of 
prisons, schools, workplaces or marginalised residential 
districts, is required. This would entail some 
consideration of how findings should be interpreted 
within the socio-political context of the research, how 
media coverage might misrepresent findings and how 
policymakers may respond. Special care is suggested in 
three areas: (1) the study design; (2) the management of 
relationships with research partners, such as prison or 
forensic authorities; and (3) how information is 
communicated to the media (Prichard et al., 2014).
I Conclusions
Concerted efforts have been made in recent years to 
improve the wastewater-based epidemiology approach 
and to reduce the uncertainties related to community 
drug use estimates. These efforts have resulted in a 
good knowledge of the critical steps of the wastewater-
based epidemiology approach and the actions required 
for improvements, as reported extensively within this 
chapter. This was made possible through the 
establishment of a European network (SCORE group) 
and the collaboration of different experts, including 
analytical chemists, drug toxicologists and sewer 
engineers. The final goal is now to start a close 
collaboration with drug epidemiologists in order to 
further discuss the opportunities for bringing together 
wastewater-based epidemiology and drug 
epidemiology.
methods. A methodological advantage of estimating 
population size from parameters measured in 
wastewater is the fact that the potential bias from flow 
measurements is cancelled out in the back-calculation 
(Lai et al., 2011). This is advantegous as it is usually very 
difficult to assess the bias resulting from flow 
measurements.
I  Ethical aspects of wastewater-based epidemiology
Because of the novelty of this field of investigation, no 
ethical rules are yet available for researchers applying 
wastewater-based epidemiology, but some general 
considerations have recently been provided (Hall et al., 
2012; Prichard et al., 2014). Hall et al. (2012) analysed 
the ethical principles that are often used for assessing 
the ethics of biomedical and epidemiological research: 
the respect for autonomy (the informed and voluntary 
consent of participants, and the maintenance of 
confidentiality and privacy), non-maleficence (the 
avoidance of harm or risks for participants), beneficence 
(the benefits from the research should outweigh any 
burdens or risks) and distributive justice (the equitable 
distribution of burdens and benefits among groups of 
participants). The application of wastewater-based 
epidemiology in the general population does not 
generally give rise to notable ethical issues, mainly 
because wastewater is collected as a composite 
sample which has been contributed to by a large 
number of people, and individuals are not identifiable 
(Hall et al., 2012). Moreover, such studies are likely to 
satisfy the principle of beneficence, since the results 
may potentially improve public health and the health of 
illicit drug users. There is a possibility of indirect harm 
caused by the stigmatisation of a particular community 
with respect to others, but this risk would normally be 
remote because of the dimensions of the catchment 
areas being investigated, which are likely to include at 
least 10 000 people. This risk will be highly influenced 
by how the media communicate research results to the 
public: accurate communication can highlight the 
benefits to society, while erroneous communications 
may result in sensationalism and stigmatisation of 
vulnerable groups (Prichard et al., 2014). Particular 
attention should therefore be paid to media 
communication, even if predicting the outcomes of the 
media coverage of an emotive topic such as illicit drug 
use is particularly difficult.
By contrast, there are greater ethical concerns, which 
require careful consideration, with regard to smaller 
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I Introduction
Wastewater-based epidemiology relies on the chemical 
analysis of the metabolic residues of a certain substance 
in urban wastewater in order to determine the 
consumption of that substance in the contributing 
population. So far, this approach has been applied to 
estimate the consumption of the most widely used illicit 
drugs (Zuccato et al., 2008; van Nuijs et al., 2011a) and, 
more recently, alcohol (Reid et al., 2011) and nicotine 
(Castiglioni et al., 2015) by measuring specific ‘target 
residues’ in raw urban wastewater.
Humans come into contact with thousands of foreign 
chemicals, medicines and xenobiotics (substances 
foreign to the body) through intentional consumption 
and accidental exposure to environmental contaminants, 
as well as through food. These substances can be 
eliminated from the body after being chemically altered 
(metabolised), or they may be eliminated unchanged. 
The human body has several means available to 
eliminate xenobiotics rapidly, so that they do not 
accumulate in the tissues and cause harm. The ability of 
humans to metabolise drugs is a natural process that 
involves the same enzymatic pathways and transport 
systems as those used for the metabolism of ‘normal’ 
dietary constituents (Brunton et al., 2011). This 
metabolism consists of a number of biochemical 
processes, which may include oxidation, reduction, 
hydrolysis, hydration, conjugation, condensation and 
isomerisation, and makes a drug easier to excrete, 
normally as a result of its transformation into a polar 
form that is more readily excreted by the kidneys (in 
urine) and the liver (in bile). For many substances, 
metabolism occurs in two phases. Phase I reactions 
involve the formation of a new or modified functional 
group or cleavage (by oxidation, reduction or hydrolysis), 
while phase II reactions involve conjugation with an 
endogenous substance (e.g. glucuronic acid, sulphate 
ions or glycine).
Urinary excretion through the kidneys is the main route 
of excretion for a complex panel of metabolic products. 
Each substance can be excreted in a variety of different 
combinations: the main metabolite; a mixture of 
metabolites excreted in similar amounts; the main 
metabolite and several minor metabolites; a mixture of 
minor metabolites; an unchanged form; or conjugated 
metabolites. All of these excretion products enter urban 
wastewater through human urine. It is therefore feasible 
to select some substances (‘target residues’), measure 
their levels using sophisticated and sensitive analytical 
techniques and back-calculate the amount of the 
corresponding parent substances ingested collectively 
by a community. This is the principle commonly applied 
to the estimation of illicit drug consumption by 
measuring selected ‘target drug residues’ in urban 
wastewater. Current research is focused on optimising 
the choice of these specific target residues in order to 
improve the reliability of the wastewater-based 
epidemiology approach (Khan and Nicell, 2011; 
Castiglioni et al., 2014). Moreover, the principles and 
specific guidelines developed for illicit drugs could be 
applied to a wide range of other substances.
This chapter collects and summarises the most recent 
guidelines for choosing target residues for wastewater-
based epidemiology: it describes the main requirements 
of a target residue that allow it to be successfully 
employed as a biomarker of drug consumption, it 
provides an overview of the target drug residues 
currently employed for estimating illicit drug 
consumption, and it describes some novel suggestions 
for the refinement and standardisation of the choice of 
specific target residues.
I  Target residue requirements for drug biomarkers
The selection of specific substances as target residues is 
not an easy task, since an ideal target drug residue 
should fulfil several specific requirements in order to 
ensure the reliability of back-calculated estimates. The 
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the high microbial activity typically found in sewers. For 
instance, it was shown that metabolites excreted as 
glucuronide conjugates are completely transformed to 
the free forms by β-glucuronidase enzymes from faecal 
bacteria in raw wastewater (D’Ascenzo et al., 2003; 
Castiglioni et al., 2006). An example of this is morphine-
3β-glucuronide, the excretion of which accounts for up 
to 38 % of a dose of heroin (Baselt, 2004), and which 
was found to completely revert to morphine within 24 
hours of storage in wastewater (Castiglioni et al., 2006). 
The evaluation of the stability of substances in 
wastewater is crucial for choosing a useful target 
residue, as demonstrated for cocaine metabolites 
(Chapter 1). Several studies have demonstrated that of 
the two most abundant metabolites of cocaine, 
benzoylecgonine is more stable in wastewater than 
ecgonine methyl ester (Gonzalez-Marino et al., 2010; 
Baker and Kasprzyk-Hordern, 2011; Castiglioni et al., 
2011; van Nuijs et al., 2012), with the latter showing 
losses of up to 40 % after 12 hours in wastewater 
(Bisceglia and Lippa, 2014). Some inconsistencies in the 
degradation rates of these two compounds were also 
observed in various studies, even within the same 
laboratory in which the same experimental conditions 
were used and only the wastewater used was different 
(Castiglioni et al., 2011). It was assumed that 
experimental set-ups and, particularly, the nature and 
composition of the wastewater substantially influence 
the biological degradation of these substances; thus, 
these parameters should be tested carefully in each 
specific case.
So far, stability experiments have been conducted only 
in laboratories in which ‘real conditions’ for temperature 
and sewage composition are simulated, because of the 
obvious difficulties with regard to performing such 
experiments under ‘real’ conditions. An alternative 
method is based on modelling studies, but only one such 
study has been performed (Plosz et al., 2013). Therefore, 
it is important that sewer experiments are designed and 
additional modelling studies are performed to 
investigate the in-pipe biotransformation of target 
residues and to confirm the current data.
Adsorption of compounds onto solid particulate matter 
is another phenomenon that can occur in wastewater 
and which can affect the stability of a substance. 
However, it was recently demonstrated that this is not an 
important factor in relation to illicit drugs because the 
percentage of such compounds adsorbed onto 
particulate matter is usually relatively low. For example, 
the adsorption of cocaine is less than 3.1 %, for 
benzoylecgonine adsorption is less than 0.5 %, for 
amphetamine it is less than 8.6 %, for MDMA it is less 
than 2.4 % and for methamphetamine it is less than 
main requirements are that it should be excreted in 
consistent amounts in urine; it should be detectable in 
urban wastewater; it should be stable in wastewater; and 
its only source should be human excretion.
A target drug residue should be excreted in urine in 
amounts sufficient to ensure that it will be still 
detectable in urban wastewater after considerable 
dilution. The dilution factor of a target residue in urine or 
wastewater will vary according to the size of the 
population, the sewer system and the presence of 
satellite waters (i.e. rain water, river water) converging on 
the system. A ‘typical’ dilution factor for a medium-sized 
city would be in the range of 200- to 400-fold during dry 
weather conditions, but two to five times higher than this 
during rain events. Moreover, a stable daily per-capita 
excretion with low intra- and interindividual variability, 
and therefore a stable flow in wastewater, is also a 
desirable characteristic for a target drug residue. This 
can be evaluated from the consumption frequency of a 
substance and from its pharmacokinetic profile (if 
available), for example its excretion rate and plasma and 
urine half-lives; however, the interindividual excretion 
rate can vary and this largely depends on individuals’ 
metabolism. In a sewer system collecting waste from 
thousands, or even millions, of people (i.e. cases in 
which wastewater-based epidemiology is typically 
applied), these differences are levelled out by the large 
number of people contributing to the waste; therefore, 
interindividual variations in excretion are likely to result in 
serious biases for only very small communities (< 10 000 
population).
The analytical techniques used to measure target drug 
residues in wastewater should be specific and selective 
enough to guarantee the detection of a compound, even 
if it is present at only trace levels (in the low ng/l range). 
However, substances excreted at very low levels could 
be difficult to detect, and this should be checked 
carefully in advance. Unfortunately, urban wastewater is 
a complex matrix and analyses for specific substances 
can be affected by a high signal suppression, known as 
the ‘matrix effect’, because of a large number of 
components within a sample. Thus, the use of specific 
purification techniques and reference standards (as 
described in Chapter 1) should be evaluated when 
establishing an analytical method.
Another essential requirement for a target drug residue 
is that it should be stable in wastewater, during transport 
in the sewer system, during sampling and during 
analysis; stability was recently evaluated for several of 
the target drug residues currently used for wastewater-
based epidemiology (see Chapter 1). The degradation of 
a substance in wastewater can easily occur as a result of 
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Therefore, nicotine itself cannot be used as a target 
residue for the estimation of nicotine consumption 
within a community.
I  Target residues currently used for the back-calculation of drug consumption
After the selection of an appropriate target residue and 
its measurement in wastewater, specific correction 
factors are employed to back-calculate the 
consumption of the parent substance (see Chapter 1). 
These correction factors should be selected carefully in 
order to ensure the reliability of results. A brief overview 
of the target drug residues currently measured in urban 
wastewater and used to estimate illicit drug 
consumption is presented in Table 2.1. Usually, the 
correction factor for a given residue is based on the 
average proportion of the drug consumed that is 
2.3 % (Baker and Kasprzyk-Hordern, 2011; 
Baker et al., 2012).
Finally, a target drug residue should be a product unique 
to human metabolism, and not a result of discharges 
from exogenous sources, which could lead to an 
overestimation of the final results. For instance, it was 
demonstrated that cocaine is not a suitable target drug 
residue for the estimation of cocaine consumption 
because its levels in wastewater are affected by factors 
other than consumption, such as trafficking of cocaine 
and handling (i.e. dumping) (van Nuijs et al., 2011a; 
Thomas et al., 2012). Recently, the profiles of nicotine 
and its main urinary metabolites, cotinine and trans-3′-
hydroxycotinine, were evaluated in urban wastewater 
(Castiglioni et al., 2015). Nicotine mass loads were 
higher than expected for urinary excretion, and showed 
random variability during the sampling period. This may 
indicate that other sources of nicotine, such as the direct 
disposal of ash and washout from cigarette butts, may 
contribute to the amount of nicotine in wastewater. 
TABLE 2.1
Overview of target drug residues measured in wastewater and the corresponding correction factors currently used 
for back-calculation of drug consumption
Drug Target drug residue measured in wastewater
Percentage of 
excretion (mean 
selected)
Correction 
factor used for 
back-calculation
References
Cocaine Benzoylecgonine 45
35
32.5
29
2.3
3
3.2
3.59
a,b,c,d,e,f,g,h
i,j,m
k
l
Cocaine 7.5 13 i
Amphetamine Amphetamine 30 3.3 a,c,e,f,g,h,j,k
Methamphetamine Methamphetamine 43
39
33
2.3
2.6
4.06
a,e,f,h,j,k
i
m
3,4-Methylenedioxy-
methamphetamine 
(MDMA)
MDMA 65
26
20
15
1.5
3.9
5
6.7
a,c,e,g,h
f
j,k
i
Cannabis 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol 
(THC-COOH)
2.5
0.6
36.4
152
f
a,c,e,g
Codeine Codeine 70 1.4 c
Heroin Morphine 42 3.1 a,c,e,h
6-Monoacetylmorphine 1.3 86.9 f,j
Methadone Methadone 27.5 3.6 f
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
(EDDP)
30.9
13
3.4
6.3
k
g
Ephedrine Ephedrine 75 1.3 e,f,h
Oxycodone Oxycodone 14 221 h
Ketamine Ketamine
Norketamine
30
1.6
3.3
65
h
m
(a) Zuccato et al., 2008; (b) van Nuijs et al., 2009; (c) Terzic et al., 2010; (d) Metcalfe et al., 2010; (e) Postigo et al., 2010; (f) Postigo et al., 2011; (g) Nefau et 
al., 2013; (h) Yargeau et al., 2014; (i) Lai et al., 2013a; (j) van Nuijs et al., 2011b; (k) Baker et al., 2012; (l) Castiglioni et al., 2013; (m) Lai et al., 2013b.
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use levels (van Nuijs et al., 2011a). For instance, 
amphetamine can also result from the metabolism of 
methamphetamine (up to 7 % of methamphetamine is 
excreted as amphetamine) and other illicit substances, 
such as the stimulant product fenethylline (27 % is 
excreted as amphetamine), the appetite suppressant 
fenproporex (38 % is excreted as amphetamine) (Baselt, 
2004) and the anti-Parkinson drug selegiline (Maurer 
and Kraemer, 1992). Amphetamine can also be 
prescribed to treat specific disorders, such as attention 
deficit–hyperactivity disorder (Burgard et al., 2013). 
Similarly, methamphetamine is also a metabolic by-
product of selegiline and of the analgesic and antipyretic 
agent famprofazone, and of the anorectic 
pharmaceutical benzphetamine (Maurer and Kraemer, 
1992; Baselt, 2004).
I Cannabis
The main metabolite of cannabis, THC-COOH, is used as 
a target residue and, usually, a single correction factor 
(of 152) is used. Because of the relatively low 
percentage of cannabis that is excreted as THC-COOH 
— which results in a high correction factor and, thus, 
less precise estimates of consumption levels — specific 
studies should be performed to address the possibility 
of also using other metabolites, such as 11-hydroxy-
delta-9-tetrahydrocannabinol (THC-OH), to estimate 
cannabis use levels. Nevertheless, there are some 
analytical challenges related to the chemical analysis of 
these metabolites, and the potential for these 
substances to partition to particulate matter, which 
could reduce their availability in wastewater, should also 
be investigated.
I Heroin
Morphine is the most abundant metabolite of heroin and 
can be used as a target residue to estimate heroin 
consumption; but morphine found in wastewater is also 
an indicator of the therapeutic use of morphine and 
codeine. Hence, when back-calculating heroin 
consumption based on wastewater morphine levels, 
correction factors that compensate for the contributions 
from therapeutic morphine and codeine must be applied 
(Zuccato et al., 2008). Alternatively, 6-acetylmorphine, a 
minor but exclusive metabolite of heroin (excretion rate 
1.3 %; Baselt, 2004), could be used to estimate the 
consumption of this illicit drug; however, in general, only 
low concentrations of 6-acetylmorphine are found in 
wastewater and some degradation has been reported 
(van Nuijs et al., 2012).
excreted in the form of that residue. It also takes into 
account the molecular mass ratio of the parent drug to 
the metabolite (Zuccato et al., 2008). As shown in 
Table 2.1, the target drug residues currently used are 
either the illicit drugs themselves (i.e. amphetamine, 
methamphetamine and MDMA) or metabolites of the 
drugs (i.e. benzoylecgonine for cocaine, 11-nor-9-
carboxy-delta-9-tetrahydrocannabinol (THC-COOH) for 
cannabis, and morphine or 6-acetylmorphine for 
heroin).
I Cocaine 
Most of the wastewater-based epidemiology studies 
available concern the estimation of cocaine 
consumption; benzoylecgonine is the most frequently 
used target residue in these studies because of its 
suitability as a biomarker, as discussed previously. 
However, different correction factors for the back-
calculation of cocaine consumption have been employed 
in previous years, ranging from 2.3 to 3.2. More recently, 
a refined correction factor was proposed in order to 
standardise the back-calculation of cocaine use 
(Castiglioni et al., 2013). This was made possible by a 
thorough review of all the pharmacokinetic studies 
available in the literature and the development of a novel 
method of obtaining a refined correction factor (see 
Improved method to calculate correction factors, page 
39, for detailed information).
I Amphetamine-type stimulants 
The parent drug is used as the target residue for 
estimations of amphetamine-type stimulant use. For 
amphetamine, only one correction factor has been 
developed, while for methamphetamine and MDMA, 
correction factors range from 2.3 to 4.1 and from 1.5 to 
6.7, respectively. In the case of MDMA, some new 
studies have been published in recent years which have 
allowed the revision of the previously used excretion 
percentages. Another promising tool for the 
differentiation of consumption and direct disposal of 
illicit substances is enantiomeric profile analysis (see 
‘Enantiomeric profiling of illicit drugs’ in Chapter 1). 
These drugs are metabolised in an enantioselective 
manner in the human body; therefore, the enantiomeric 
profile in urine and wastewater after human 
consumption and metabolism is different from the 
profile that results from the direct disposal of the parent 
substance. In the case of substances for which the 
parent drug is directly measured in wastewater as the 
target residue, the presence of additional sources should 
be carefully assessed to avoid overestimation of drug 
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profiles resulting from different routes of administration, 
but also the number of subjects involved in each study 
and the frequency of use of a substance for each route 
of administration (Castiglioni et al., 2013). Cocaine was 
chosen for this preliminary study because its excretion 
profiles are relatively well described for the main routes 
of administration (i.e. intravenous, intranasal and oral 
administration, and through smoking). Since 
benzoylecgonine is the most reliable target drug residue 
for the back-calculation of cocaine consumption, all of 
the pharmacokinetic studies available in the literature 
that report data on the excretion profile of 
benzoylecgonine were reviewed.
Table 2.2 shows the mean percentage of 
benzoylecgonine, calculated for each route of 
administration by weighting the mean excretion of each 
study by the number of subjects included. The mean 
excretion profile of benzoylecgonine ranged from 14 % 
(when administered by smoking) to 55 % (oral 
administration) of an administered dose of cocaine 
depending on several factors, such as the route of 
administration, the habits of consumption, the amount of 
a dose and an individual’s metabolism. Notable 
differences were observed among the different routes of 
administration, but also among the subjects treated 
through the same route of administration. All available 
information, with the exception of data from the very 
small study on oral cocaine use, was therefore used to 
revise the estimated excretion rate (taking into account 
the number of subjects in each study), which resulted in 
a mean excretion rate of 27 %, which was finally 
weighted by the frequency of cocaine use for the 
different routes of administration to obtain a mean of 
29 %. Considering this excretion value, a new refined 
correction factor of 3.59, calculated considering the 
mean excretion rate and the molar mass ratio of the 
parent drug to its metabolite, as described elsewhere 
(Zuccato et al., 2008), was proposed.
I Other substances
Other substances have been included as target residues 
in a few studies (mostly only in one), as listed in 
Table 2.1, but, in general, only one correction factor is 
used to estimate their consumption.
This overview highlights that for a number of substances 
(cocaine, MDMA and methamphetamine) different 
correction factors have been used in the various studies 
carried out to date and these differences can limit the 
comparability of results between studies. Further 
research is therefore required to refine correction factors 
in order to harmonise and standardise the methods 
employed for the estimation of drug use. Several 
attempts to do this have been made in Europe by the 
SCORE group (Chapter 1) and some additional 
proposals are reported below.
I  Improved method to calculate correction factors
It has been known for some time that most of the bias 
associated with correction factors is due to the limited 
number of pharmacokinetic studies available for illicit 
drugs and the small number of subjects involved in most 
of these studies (Zuccato et al., 2008). More recently, 
the need to conduct a comprehensive meta-analysis of 
metabolic disposition studies in order to construct 
excretion profiles for illicit drugs was suggested, and this 
has been implemented for some substances (Khan and 
Nicell, 2011, 2012).
This suggested approach was further improved in a 
subsequent study in which correction factors were 
refined by taking into account not only the excretion 
TABLE 2.2
Benzoylecgonine excretion (mean ± standard deviation) after different routes of administration of cocaine: summary 
of the data available in the literature
Route of 
administration
Number of studies
Number of subjects
(range per study)
Mean excretion (1) 
weighted by 
subjects (%)
Mean excretion 
(%) (2)
Mean excretion (%) 
weighted by route 
of administration (3)
Intranasal 9 56 (2–7) 29.4 ± 7.4
27.1 ± 11.4 29.2 ± 7.8
Intravenous 7 28 (1–7) 37.3 ± 9.6
Smoking 3 20 (5–9) 14.8 ± 5.8
Oral 1 2 55 ± 7.1
(1)  Excretion of benzoylecgonine as a percentage of cocaine consumed. 
(2)  Oral administration was not considered in the analysis because it was used by only two subjects and was, therefore, a minor route of administration.
(3)  Calculated by assuming the following pattern of consumption of cocaine: 95 % used intranasally, 2 % used intravenously and 4 % consumed by 
smoking (Prinzleve et al., 2004).
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system; these high loads may have resulted from the 
direct disposal of unused drugs or production waste 
from, for example, illegal manufacturing facilities (Emke 
et al., 2013). This makes the epidemiological estimation 
of community-wide drug use via wastewater analysis 
difficult and potentially unreliable; therefore, new 
approaches are required to distinguish between drugs in 
wastewater that result from consumption and those that 
result from the direct disposal of unused drugs. In this 
regard, one option that has been explored is the 
enantiomeric profiling of drugs in wastewater by chiral 
chromatography (see Chapter 1). Another potentially 
valid option is to search for target drug residues among 
urinary metabolites that can originate only from human 
consumption of a substance. A review of all of the MDMA 
metabolites excreted in human urine and reported in 
pharmacokinetic studies (Table 2.4) allowed us to 
identify a panel of metabolites (e.g. 4-hydroxy-3-
methoxymethamphetamine (HMMA) and 3,4-dihydroxy-
methamphetamine (HHMA)) that are excreted in 
percentages (> 10 %) sufficient for detecting target drug 
residues.
I Research needs and conclusions
The application of back-calculation approaches to the 
estimation of drug use relies on specific correction 
Since most of the correction factors currently used 
(Table 2.1) were developed several years ago, they 
should be revised to include the most recent information 
on pharmacokinetics, if available in the literature, and 
should adopt the new comprehensive methodologies of 
processing and analysing data. The methods proposed 
for cocaine could be applied to other substances, not 
only to update the currently used correction factors, but 
also to increase the panel of potential target drug 
residues.
New information can also be used to revise the 
correction factors used for the wastewater-based 
estimation of MDMA consumption, for which the drug 
itself is the target residue. MDMA has one main route of 
administration (oral) and the current correction factor 
(1.5) is based on a mean percentage excretion of 65 %; 
however, this excretion rate value can now be revised to 
take into account the most recent information on the 
drug’s excretion profile and by applying the method 
described above. Considering this additional 
information, presented in Table 2.3, the revised mean 
percentage of excretion for MDMA is now estimated to 
be approximately 20 %, which is markedly different from 
the previous value of 65 %.
High loads of MDMA, which could not be explained 
solely by the consumption of this illicit drug by the 
specific community, were recently observed in a sewer 
TABLE 2.3
List of the main pharmacokinetic studies reporting the excretion profile of MDMA and the calculated mean 
percentages of excretion for each study
Dose Subjects treated
Duration of the study 
(hours)
Mean excretion (%) References
50 mg 1  0–72 65 Verebey et al., 1988
125 mg 1  0–24 30 Ortuño et al., 1999
100 mg 4  0–24 15.0 Segura et al., 2001
100 mg 6  0–24 23.9 Pizarro et al., 2002
100 mg 7  0–72 22 Pizarro et al., 2004
40 mg 8  0–24 33.1 Fallon et al.,1999
1 mg/kg 5 0–120 13.7 Abraham et al., 2009
TABLE 2.4
MDMA metabolites excreted in human urine
Target residue Mean excretion (%)
3,4-Methylenedioxy-methamphetamine (MDMA) 13.4 
3,4-Methylenedioxy-amphetamine (MDA)  1.1 
4-Hydroxy-3-methoxymethamphetamine (HMMA)  9.6 
4-Hydroxy-3-methoxyamphetamine (HMA)  0.9 
3,4-Dihydroxy-methamphetamine (HHMA) 17.7
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factors, which mainly take into account the urinary 
metabolism of a substance. Unfortunately, human 
pharmacokinetic data are very scant for most of the 
main illicit drugs, and the available studies, in general, 
were not performed recently and are based on a small 
number of subjects. Some of these studies also 
considered doses that are lower than those commonly 
used by drug users and administered through atypical 
routes (Verstraete, 2013), while other studies included 
only one sex (e.g. males) or only one race (e.g Caucasian) 
(Bruno et al., 2014). Thus, the results from such studies 
are unlikey to reflect a typical, real-world situation in 
which both males and females are likely to consume a 
given drug, sometimes in multiple doses, via different 
routes or in conjunction with various other substances.
All of these factors could affect the metabolic profile of a 
drug and hence the accuracy of the excretion profile 
used to back-calculate consumption. The main limitation 
of this type of approach is related to the complexity of 
performing pharmacokinetic studies, as these require 
specific authorisations and adherence to strict ethical 
rules and can, therefore, be performed only in specific 
research centres. Despite this, there is an urgent need 
for new pharmacokinetic studies of illicit drugs. Such 
studies should include an adequate number of subjects 
and test realistic drug dosages using all of the main 
routes of administration. It would also be desirable to 
have data from studies on new psychoactive drugs for 
which human metabolism is mostly unknown.
Because of the difficulties associated with performing 
pharmacokinetic studies, an alternative technique has 
recently been suggested for the identification of the 
main metabolic products of illicit drugs; this technique 
involves using sub-cellular human liver models, such as 
pooled liver microsomes or heterologically expressed 
human enzymes (Meyer and Maurer, 2011). A few 
studies using these liver models have recently been 
conducted on some new psychoactive substances, such 
as the N-ethyl homologue of mephedrone, 4-methyl-N-
ethyl-cathinone (4-MEC), which belongs to the beta-keto 
amphetamine (cathinone) group (Helfer et al., 2015), and 
the hallucinogenic designer drug 2,5-dimethoxy-4-
propylphenethylamine (2C-P) of the phenethylamine 
class (Wink et al., 2014). The aim of these studies was to 
investigate the phase I and phase II metabolism of the 
selected substances in human urine, as well as in pooled 
human liver microsome incubations. The metabolites 
were identified by gas chromatography–mass 
spectrometry and by liquid chromatography–high-
resolution tandem mass spectrometry. Based on the 
metabolites identified in urine or pooled human liver 
microsomes, several metabolic pathways were proposed 
for each substance.
It is vital that more information on the pharmacokinetics 
of illicit drugs is obtained in order to improve the 
reliability of wastewater-based epidemiology; thus, the 
use of sub-cellular models is likely to be a valuable 
alternative tool to ‘classical’ pharmacokinetic studies. 
Nonetheless, it is also very important that new 
pharmacokinetic studies, able to reflect ‘real situations’ 
of drug consumption within a population, are performed. 
Finally, until further pharmacokinetic information is 
available, it is highly recommended that reliable 
correction factors, based on meta-analyses of all 
available data and determined in accordance with the 
methodologies recently proposed, are used.
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I Introduction
Wastewater-based epidemiology is considered to be a 
powerful approach for monitoring patterns and trends of 
illicit drug use within a community (van Nuijs et al., 
2011a). Since 2005, this approach has been applied in 
several countries worldwide (Castiglioni et al., 2014). The 
number of research groups working in this field is 
growing continuously and the available knowledge has 
enormously improved. Figure 3.1 shows how the number 
of publications related to wastewater analysis has 
increased progressively since 2004.
Spatial and temporal patterns of use of the main illicit 
drugs (cocaine, cannabis, amphetamine, 
methamphetamine and MDMA) have been evaluated in 
urban areas, including several main cities and 
megalopolises, as well as in rural areas and during special 
events. These assessments have highlighted some 
common profiles of use, such as the weekly patterns of 
consumption, but also notable geographical differences in 
the consumption of specific substances. To date, 
wastewater analysis has mostly been used to estimate 
local consumption in major cities (see the Appendix), but it 
has also been applied on larger scales to allow the 
identification of differences in cocaine use in large and 
small cities in Belgium (van Nuijs et al., 2009); in cocaine, 
methamphetamine and MDMA use in urban and rural 
areas in Oregon, United States (Banta-Green et al., 2009); 
and in cocaine, MDMA, amphetamine and cannabis use in 
25 cities in France (Nefau et al., 2013). Moreover, a 
European study was performed in 2011 and showed, for 
the first time, the distinct spatial patterns of drug use 
across 19 European cities; the results of this study were, in 
general, in good agreement with officially reported 
prevalence data (Thomas et al., 2012) (see below for a 
more detailed description). An increase in 
methamphetamine consumption at weekends was found 
by 1-month monitoring campaigns in Oslo, Norway (Reid 
et al., 2011a), and in Adelaide, Australia (Irvine et al., 2011).
The monitoring of drug use though wastewater analysis 
also allowed changes in drug use over time to be 
tracked, and new drug use patterns to be identified. For 
example, a wastewater analysis study conducted in the 
north of Italy between 2008 and 2009 (Zuccato et al., 
2011) demonstrated a marked decrease in cocaine and 
heroin use in two cities during this time; this decrease 
was subsequently confirmed in 2012 by national 
epidemiological surveys (DPA, 2012). Other changing 
patterns of use have been observed in Australia as a 
result of wastewater analysis. For example, a decrease in 
cocaine consumption was observed in Queensland 
between 2009 and 2010 (Prichard et al., 2012), and a 
simultaneous decrease in MDMA use was also identified 
in Adelaide (Chen et al., 2011, 2013). In addition, some 
differences in the use of cocaine (increase) and 
methamphetamine (decrease) were recently found in the 
United States compared with the use levels estimated 
by previous studies on these drugs (Subedi and Kannan, 
2014). The temporal patterns of consumption evaluated 
by a 4-year monitoring campaign in about 20 European 
cities were reported recently (EMCDDA, 2015); the 
results of this campaign are described in detail below 
(see next paragraph).
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FIGURE 3.1
The number of publications (combined PubMed search) 
related to wastewater-based epidemiology per year 
since 2004
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regional differences in illicit drug use in Europe based 
upon wastewater analysis. Additional studies were 
performed in 2012, 2013 and 2014 on an increasing 
number of cities (23, 42 and 50, respectively), each year 
with an intercalibration exercise (Ort et al., 2014; 
EMCDDA, 2015).
This project revealed distinct geographical and temporal 
patterns of drug use across European cities. A general 
description of the study findings is provided in this 
chapter, and detailed figures are presented in EMCDDA 
(2015). 
Although substantial fluctuations in individual cities 
were observed, the general geographical patterns of 
drug use were relatively stable over the four years 
(2011–2014). Cocaine use, estimated by measuring 
benzoylecgonine loads, as described in Chapter 2, was 
highest in cities in the west and south of Europe and 
lowest in cities in the north and east (Figure 3.2). 
Methamphetamine consumption was highest in the 
Czech Republic, Slovakia and northern Europe, while in 
all other countries, methamphetamine use seemed to be 
very low or even negligible. For amphetamine, the 
highest loads were detected in northern and north-
western European cities.
Relatively low levels of urinary biomarker loads related to 
MDMA were found in most of the European countries 
studied. For 2011–2013, the highest loads by far were 
detected in Belgian and Dutch cities. In 2014, London 
and Oslo also reported high loads of MDMA in 
wastewater.
With regard to cannabis, the quantification of THC-
COOH (11-nor-9-carboxy-delta-9-tetrahydrocannabinol) 
loads in wastewater poses some analytical challenges, 
and, as a result, not all samples were analysed for this 
metabolite of THC. Therefore, in contrast to the other 
illicit drugs under investigation, it was not possible to 
establish regional patterns for cannabis use.
The study also highlighted differences among cities 
within the same country, which could be explained in 
part by the different social and demographic 
characteristics of different cities (e.g. whether or not 
they have universities or nightlife areas, and the age 
distribution of the population). In the majority of 
countries with multiple study locations, cocaine and 
MDMA loads were generally higher in large cities than in 
towns. No such differences were detected for 
amphetamine or methamphetamine loads.
In addition to geographical patterns, wastewater 
analysis can detect fluctuations in weekly patterns of 
Wastewater analysis has also been applied successfully 
on a small scale to assess drug use in specific 
populations, such as in prisons (Postigo et al., 2011; 
Brewer et al., 2014), in schools (Panawennage et al., 
2011; Burgard et al., 2013), in an airport (Bijlsma et al., 
2012) and in different districts within a city (Reid et al., 
2011b). It was also used to study fluctuations in drug 
consumption, mostly increases in cocaine and MDMA 
use, during special holidays or in vacation areas or 
holiday resorts (Reid et al., 2011b; van Nuijs et al., 2011b; 
Lai et al., 2013a) and during special music or sporting 
events (Bijlsma et al., 2009; Gerrity et al., 2011; Lai et al., 
2013c).
The numerous studies available in the literature on 
wastewater analysis confirm the potential of this 
approach for monitoring the temporal and spatial trends 
of drug use on different scales (i.e. local, national and 
international). The particular pattern of drug use may 
also be studied at specific sites, such as rural or vacation 
areas, at different times of the year and during special 
events, in order to provide information to complement 
epidemiological surveys that normally collect 
information about the previous month or year, or the 
lifetime prevalence of use. Several studies have also 
shown that wastewater analysis is able to provide 
repeated estimates of drug use and that the approach 
can be used to quickly identify changing patterns of use.
This chapter provides an overview and comparison of the 
results obtained by applying wastewater-based 
epidemiology in Europe, the United States, Canada, 
Australia and Asia.
I  A European collaboration: results of a 4-year long monitoring campaign
In 2010, a Europe-wide network (Sewage Analysis CORe 
group – SCORE) was set up with the aims of 
standardising the methodologies used for wastewater 
analysis and coordinating international studies. The first 
coordinated monitoring study was performed in March 
2011, whereby wastewater analysis was simultaneously 
applied in 19 European cities over a 1-week period 
(Thomas et al., 2012). Within this study, a common 
protocol of action (best-practice protocol), as described 
in Chapter 1, was applied for the first time. Urinary target 
residues of cocaine, amphetamine, MDMA, 
methamphetamine and cannabis were measured by 
different laboratories using in-house optimised and 
validated analytical methods. This international study 
provided the first ever comparative information on the 
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illicit drug use. In the majority of cities, higher loads of 
benzoylecgonine and MDMA were detected on 
Saturdays and Sundays than on weekdays (Figure 3.3). 
In contrast, cannabis and methamphetamine use were 
found to be distributed more evenly over the whole 
week.
The results delivered by the SCORE project were 
consistent with standard monitoring data, demonstrating 
that wastewater-based epidemiology can be 
successfully applied to the assessment and comparison 
of the use of illicit substances at local and international 
levels, and to the detection of changes in the use of a 
substance. The results were generally in good agreement 
with officially reported national prevalence data for 
Europe (EMCDDA, 2010). Nevertheless, some limitations 
should be noted in order both to improve future studies 
at the international level and to acknowledge the caution 
that must be applied when comparing results from 
different sources. Firstly, the ranking of the city-based 
estimates reported in this study would not agree with 
FIGURE 3.2
Loads of benzoylecgonine and methamphetamine (mg/day/1 000 population) in the European cities included in a 
4-year investigation (2011–2014)
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FIGURE 3.3
Loads of benzoylecgonine (mg/day/1 000 population) in 
a selection of European cities (in 2014)
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during other periods throughout the year (van Nuijs et al., 
2011b).
The first study to evaluate the use and trends of use of 
drugs in a prison through wastewater analysis was 
conducted in Spain (Postigo et al., 2011). Daily use of 
cannabis and cocaine was detected, while heroin, 
amphetamine, methamphetamine and ecstasy use was 
detected only sporadically. Some other substances, 
such as methadone, used to treat heroin dependence, 
the benzodiazepine alprazolam and ephedrine, were also 
found in all samples tested. This study demonstrated for 
the first time that wastewater-based epidemiology can 
provide ‘near-real-time’ information on collective drug 
use in an anonymous way in small communities.
I  Wastewater-based epidemiology in the United States and Canada
I Estimation of illicit drug use in the United States
The first ever measurements of illicit drugs 
(methamphetamine and MDMA) in urban wastewater 
were performed on the effluents of three wastewater 
treatment plants in Nevada, Utah and South Carolina 
(Jones-Lepp et al., 2004), where these substances were 
found at very low concentrations (about 1 ng/l). Later, in 
2009, methamphetamine was detected at higher 
concentrations in the effluent from one wastewater 
treatment plant in Nevada (350 ng/l) and in several 
rivers upstream and downstream of this wastewater 
treatment plant at concentrations ranging from 1 to 
60 ng/l (Bartelt-Hunt et al., 2009). The first study to use 
wastewater-based epidemiology was performed during 
the same period in seven different wastewater treatment 
plants in the United States, and several classes of illicit 
drugs (cocaine, amphetamines, opioids, ketamine and 
LSD (lysergic acid diethylamide)) were measured in 
influent wastewater (Chiaia et al., 2008). 
Methamphetamine loads were the highest yet reported, 
while cocaine loads were similar to those observed in 
western European locations. Ketamine was detected at 
very low levels, indicating sporadic use. One of the most 
comprehensive studies performed to date to evaluate 
the spatial epidemiology of illicit drugs was conducted in 
the state of Oregon, where 96 municipalities, 
representing 65 % of the population, were investigated 
with regard to cocaine, methamphetamine and MDMA 
use (Banta-Green et al., 2009). Benzoylecgonine loads, 
which indicate cocaine use, were significantly higher in 
urban than in rural areas and were, in fact, below the 
level of detection in many rural areas. Conversely, 
methamphetamine was present in all municipalities, 
national-based estimates, because of the differences in 
demographics. The wastewater studies mainly included 
one or two cities per country, often chosen from the 
main cities, while most available standard drug 
epidemiological data reflect national levels of drug use. 
According to the epidemiological literature, urban areas 
tend to have a higher prevalence of drug use than rural 
areas. For that reason, it is difficult to extrapolate 
city-based estimates to the national level and, therefore, 
specific criteria should be taken into account (Ort et al., 
2014).
The 2013 SCORE study covered a population of 
25 million people (about 5 % of the EU population); 
however, in addition to the problems discussed with 
extrapolating estimates to national levels, it is also 
difficult to extrapolate these results to the whole of 
Europe. Finally, this study used 1-week sampling periods 
for each year, which were assumed to indicate the 
pattern of use for the entire year; however, whether or 
not this sampling strategy is sufficient to obtain reliable 
annual estimates, considering potential variation due to 
time of year and special events, remains to be verified. In 
fact, some drugs may display seasonal or event-related 
variation which might only be captured by longer and 
specifically designed sampling campaigns. Future 
monitoring campaigns should therefore include more 
cities with varying demographics within a country, and 
evaluate monitoring design strategies to find an 
optimum with feasible logistics, economic effort, 
sufficient quality control and representativeness for an 
entire year and an entire country. An additional 
confounding factor which should be considered in future 
studies is the presence of dumping or discharge from 
production laboratories. This was particularly apparent 
for amphetamine and MDMA in the Netherlands (and to 
some extent in Belgium) (Thomas et al., 2012; Emke et 
al., 2014; EMCDDA, 2015), and some methods to 
overcome this limitation have been suggested (see 
‘Enantiomeric profiling of illicit drugs’ in Chapter 1).
Some studies have been conducted to evaluate changes 
in drug use during special events or holiday periods. The 
first of these studies was published in 2009 and 
reported increases in benzoylecgonine and MDMA 
during a major music event in Spain (Bijlsma et al., 
2009). In Norway, increases in the cocaine flow in 
sewage were observed during a weekend that included a 
national day of celebration in Oslo and also during the 
closing party weekend at a Norwegian ski resort, 
compared with regular weekends (Reid et al., 2011b). A 
1-year study conducted in Brussels, Belgium, on the 
main illicit drugs highlighted interesting patterns of use: 
cocaine, amphetamine and MDMA use levels were 
significantly higher during the New Year holiday than 
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concentrations of these substances detected confirmed 
the expected trend: substance levels were generally 
highest during the final exam period, medium during a 
normal class session and mostly below the limits of 
detection during the summer. These results indicate a 
possible increase in the use of psychoactive substances 
during periods of high stress. This was confirmed in a 
second study conducted on a college campus in which 
amphetamine and ritalinic acid, contained in 
medications used to treat attention deficit–hyperactivity 
disorder, were monitored during low-stress and high-
stress periods. Amphetamine use increased during 
periods of high stress, such as during the mid-term exam 
period, during the final week of classes and during the 
final exam period, when the highest peak of 
amphetamine use over baseline (760 %) occurred 
(Burgard et al., 2013).
Wastewater analysis was also used to monitor cocaine 
and methamphetamine use in a prison in the United 
States (Brewer et al., 2014) and the results indicate that 
this approach can provide information regarding the 
frequency of use of illicit drugs that cannot be obtained 
by conventional approaches, such as random urine 
analysis. In fact, methamphetamine was detected in all 
investigated wastewater samples, whereas the drug was 
detected only in 6 out of 243 tested urine samples. 
However, the wastewater study may be biased, as it was 
unable to differentiate between methamphetamine 
originating from inmates and that from employees and 
visitors; therefore, this should be evaluated in future 
studies. Cocaine was not found in any of the wastewater 
samples from this prison. This study also showed a 
different pattern of drug use from a previous Spanish 
prison study in which cocaine and benzoylecgonine were 
quantified in all daily samples; in this study, 
methamphetamine was infrequently detected (Postigo 
et al., 2011).
I Estimation of illicit drug use in Canada
Wastewater-based epidemiology was applied in Canada 
in two successive studies (Metcalfe et al., 2010; Yargeau 
et al., 2014), which were conducted in three and two 
Canadian cities, respectively. The size of the cities 
ranged from 1.6 million inhabitants (a large city in 
Canada) to 75 000 inhabitants (a small community). The 
results of the two studies were consistent, and cocaine 
was found to be the most used illicit substance tested, 
with the highest levels of consumption in the largest city. 
The highest levels of methamphetamine use were also 
detected in the largest city, while the use of 
amphetamine and MDMA was similar in large and small 
cities. Generally, the community drug consumption 
whether rural or urban, and MDMA was found in less 
than half of the communities, with a trend towards 
higher loads in more urban areas. The distribution of the 
wastewater-derived drug loads corresponded with 
expected epidemiological drug patterns; thus, this study 
provides evidence for the utility of the wastewater 
approach for spatial analyses and shows its potential to 
improve the existing estimates of the level and 
geographical distribution of drug use (Banta-Green et al., 
2009).
A recent study conducted in the Albany area, New York, 
found evidence of comparatively high levels of use of 
cocaine, amphetamine and MDMA (Subedi and Kannan, 
2014). Cocaine use estimates (mean benzoylecgonine 
loads of 2 315 mg/day/1 000 population) were four 
times higher than those reported previously for other 
states (Chiaia et al., 2008) and two times higher than the 
mean values reported for Europe (Ort et al., 2014). The 
amphetamine and MDMA loads reported by this study 
were, in general, higher than those reported previously 
for other parts of the United States and in Europe. In 
particular, amphetamine loads (mean of 244 mg/
day/1 000 population) were two and eight times higher 
than the mean loads found in the United States and 
Europe, respectively, and MDMA loads (mean of 52 mg/
day/1 000 population) were four and two times higher 
than the mean loads found in the United States and 
Europe, respectively. In contrast, methamphetamine 
loads were much lower than those found in other parts 
of the United States in 2009 (8.6 versus 427 mg/
day/1 000 population) and those reported recently as 
European mean values (25 mg/day/1 000 population).
Some interesting studies of wastewater-based 
epidemiology have been conducted in the United States, 
for example to identify a correlation between major 
sporting events and illicit drug use (Gerrity et al., 2011) 
and to assess the pattern of drug use in small 
communities, such as schools (Panawennage et al., 
2011; Burgard et al., 2013) and prisons (Brewer et al., 
2014).
Gerrity et al. (2011) measured the content of illicit drugs 
in wastewater during the weekend of the National 
Football League’s Super Bowl and found that the only 
changes relative to a baseline weekend were in the 
concentrations of methamphetamine and MDMA, which 
showed a slight increase. 
In another study, the use of the main illicit drugs 
(cocaine, amphetamines and cannabis) by a student 
population was monitored by wastewater analysis during 
a normal class session, the final exam period and the 
summer break (Panawennage et al., 2011). The 
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Another survey was conducted in South-East 
Queensland and reported similar results for MDMA and 
methamphetamine, but benzoylecgonine loads were 
five to six times higher (Lai et al., 2011). This may 
suggest the presence of different geographical 
patterns of cocaine use within Australia, as indicated 
by the differences between South Australia and 
South-East Queensland. Cannabis consumption was 
investigated for the first time in this study and it was 
found to be the most-used substance. In general, the 
rank order of illicit drug consumption in Australia was 
cannabis followed by methamphetamine, cocaine, then 
MDMA. Shortly after this initial study, another study 
was conducted in the same area to assess the temporal 
trends of drug consumption, and two sampling 
campaigns were performed in November 2009 and 
2010 in the same wastewater treatment plant (Prichard 
et al., 2012). The results indicated notable changes in 
the levels of drugs identified in the two sampling 
periods. The average load of cocaine (estimated from 
benzoylecgonine loads) in 2009 (221 mg/day/1 000 
population) was more than four times higher than the 
average load measured in 2010 (52 mg/day/1 000 
population); thus, a significant decline in 
benzoylecgonine loads was observed. Conversely, 
methamphetamine loads increased in the same period 
from 158 to 228 mg/day/1 000 population. No changes 
were observed for MDMA loads (about 135 mg/
day/1 000 population).
One of the first studies to detect the use of new 
synthetic stimulants, cathinones and piperazines, 
through wastewater analysis was also performed in 
Australia (Chen et al., 2013). Wastewater samples were 
collected from multiple wastewater treatment plants in 
Adelaide in a 3-year monitoring campaign (2009–2011). 
MDMA was also included in this study as it was one of 
the most ‘popular’ synthetic drugs used in the years prior 
to the campaign. Firstly, a large decrease in MDMA levels 
was observed from 2009 to 2010; the levels then 
remained stable and relatively low in 2011. 
Methcathinone was found in all wastewater treatment 
plants and in all the years investigated, indicating a 
widespread and constant use of this substance. The 
other investigated drugs (mephedrone, methylone, 
methylenedioxypyrovalerone (MDPV), benzylpiperazine 
(BZP) and 3-trifluoromethylphenylpiperazine (TFMPP)) 
showed local increases, mainly in 2011, although 
mephedrone use levels had already increased in 2010. 
These results suggest that the decline in MDMA use may 
have been associated with an increase in the use of a 
number of other synthetic stimulants. However, the 
highly regionalised use of all of these substances and 
the delay between the decrease in MDMA use and the 
increase in the use of other substances indicates that 
values obtained in this study were more similar to values 
reported in Europe than to those obtained in the nearby 
United States. MDMA use peaked at weekends, as 
observed in almost all European studies. Ketamine was 
also detected in wastewater from the largest city 
(Yargeau et al., 2014) at levels similar to those previously 
detected in the United States (Chiaia et al., 2008); these 
findings indicate a potential problem related to the 
abuse of this veterinary anaesthetic in North America.
I  Wastewater-based epidemiology  in Australia
Wastewater-based epidemiology was first used in 
Australia between April and October 2009 in the state of 
South Australia to analyse wastewater from a number of 
metropolitan (population served of 150 000–800 000) 
and regional (population served of 400–23 000) 
treatment plants (Irvine et al., 2011). This study 
suggested a different pattern of drug use from that 
estimated in Europe, the United States and Canada. The 
use of cocaine was found to be much lower, and 
benzoylecgonine loads ranged from 5 to 10 mg/
day/1 000 population. In contrast, MDMA and 
methamphetamine use were similar to the use levels 
observed in other countries, with loads ranging from 15 
to 30 mg/day/1 000 population and from 40 to 65 mg/
day/1 000 population, respectively. In Australia, MDMA 
was more popular in rural areas, whereas 
methamphetamine and cocaine were mainly consumed 
in metropolitan areas; this is slightly different from the 
profiles observed in the United States, where 
methamphetamine use was widespread in rural and 
urban areas (Banta-Green et al., 2009). As observed in 
other countries, the use of these substances increased 
at weekends, with the highest increases found for 
MDMA (a five-fold increase at the weekend compared 
with weekdays).
This finding agrees with data from the 2009 World Drug 
Report (UNODC, 2009) showing that use of MDMA and 
methamphetamine was higher in Australia than in all the 
other countries during the period investigated. However, 
the consumption of MDMA and methamphetamine 
described by the Australian study was 10 to 30 times 
higher than in some European cities (i.e. Milan and 
London; Zuccato et al., 2008), and was more similar to 
the profiles found in northern and eastern Europe (Ort et 
al., 2014). In addition, survey data (UNODC, 2009) 
suggest a similar use of cocaine in Europe and Oceania, 
while the Irvine et al. (2011) study showed a different 
picture.
CHAPTER 3 I A global overview of wastewater-based epidemiology
51
ketamine was the most used substance with loads 
ranging from 270 to 300 mg/day/1 000 population as 
the parent compound, and 20 mg/day/1 000 population 
as norketamine (the urinary metabolite of ketamine); the 
second most used drug was methamphetamine (60–
70 mg/day/1 000 population), followed closely by 
cocaine (50–60 mg of benzoylecgonine/day/1 000 
population). In contrast to what has been observed in all 
other countries investigated, MDMA was not detected in 
this study.
Wastewater-based epidemiology was also applied to 
assess the levels of ten illicit drugs in several wastewater 
treatment plants in four Chinese megacities (Beijing, 
Guangzhou, Shenzhen and Shangai) (Khan et al., 2014). 
The results obtained demonstrate, in a quantitative way, 
that the drug use patterns of Chinese people are 
different from those of Europeans, North Americans and 
Australians. In fact, the use of cocaine, which in some 
cases was not detected (i.e. Beijing and parts of 
Shangai), and MDMA appeared to be much lower in 
China than in Europe, the United States and Australia, 
with median loads of 5.6 and 1.5 mg/day/1 000 
population, respectively. In Chinese megacities, much 
higher loads were found for methamphetamine (median 
109 mg/day/1 000 population), ketamine (median 
230 mg/day/1 000 population) and amphetamine 
(median 42 mg/day/1 000 population). The other 
substances investigated, cannabis, heroin and new 
psychoactive substances (mephedrone and 
methylenedioxypyrovalerone), were not found, which 
indicates their very low or non-existent use. The use of 
most of the drugs detected showed a geographical 
trend, with a much higher use observed in the southern 
(Shenzhen and Guangzhou) than in the northern cities 
(Beijing and Shanghai). The results observed for the 
southern cities were also very similar to those previously 
reported for Hong Kong (Lai et al., 2013b). The overall 
results were largely consistent with trends reported by 
the United Nations Office on Drugs and Crime (UNODC, 
2013).
Different areas of Beijing were further investigated with 
regard to amphetamine and methamphetamine use (Li 
et al., 2014). Methamphetamine loads ranged from 4 to 
230 mg/day/1 000 population and were similar to those 
previously reported by Khan et al. (2014). Amphetamine 
loads were low (0.4–13 mg/day/1 000 population) and 
this confirmed the hypothesis that, in Beijing, 
amphetamine comes mainly from methamphetamine 
metabolism, while the use levels of amphetamine itself 
are very low. Different patterns of use were observed for 
different areas of the city: methamphetamine loads were 
higher in the centre of the urban area, indicating a 
correlation with economic factors and the availability of 
there was not a direct population-wide substitution of 
MDMA (Chen et al., 2013).
Wastewater analysis was also used in Australia to study 
changes in drug use during specific periods of the year 
(i.e. important annual holidays) and events (i.e. a music 
festival). In the first case, an urban area, a semi-rural 
area and an island popular for vacations were 
investigated (Lai et al., 2013a). In the semi-rural area, 
drug consumption was generally low and a decrease in 
cannabis use was found during holidays. In the urban 
area, the consumption of all drugs, especially cannabis 
and cocaine, increased during holidays. In the vacation 
area (the island), the consumption of cocaine, 
methamphetamine and MDMA markedly increased 
during holiday periods, but cannabis use declined. In the 
second case, the same music festival was monitored for 
two consecutive years (2010 and 2011) to assess the 
use of conventional illicit drugs (cannabis, cocaine, 
methamphetamine and MDMA) and emerging illicit 
psychostimulants (benzylpiperazine, mephedrone and 
methylone) (Lai et al., 2013c). The first group of 
substances was found in all samples taken and their use 
was found to be generally stable over the two festival 
years, apart from a decrease in methamphetamine use. 
The second group of substances was found only on 
specific days and no defined trends of use could be 
identified. The use of conventional drugs in a nearby 
urban community was also monitored and compared 
with the use at the music festival. MDMA was the only 
substance for which use was higher at the festival than 
in the nearby community (Lai et al., 2013c).
I  Wastewater-based epidemiology  in Asia
The levels of illicit substances were assessed, for the 
first time, in wastewater treatment plant effluents and 
surface water in Asia in Taipei, Taiwan, by Lin et al. 
(2010). Morphine, codeine, methamphetamines and 
ketamine were observed in significant quantities (up to 
hundreds of ng/l) in hospital effluents, wastewater 
treatment plant effluents and in river waters.
Since this initial study, few studies have been conducted 
to assess drug use in Asia by using wastewater-based 
epidemiology. The first of these was a pilot study in 
which Hong Kong’s largest wastewater treatment plant, 
serving a community of approximately 3.5 million 
people, was analysed for cocaine, ketamine, 
methamphetamine and MDMA (Lai et al., 2013b). The 
overall drug use pattern detected was as follows: 
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However, trying to compare results from different 
wastewater-based studies can be particularly 
challenging if non-homogeneous data are reported and 
this overview of results presented some examples. For 
instance, in most of the studies, the results were 
reported as loads per day of a target substance (e.g. 
benzoylecgonine for the assessment of cocaine use) and 
they were then normalised to 1 000 population; but, in 
some cases, the loads were transformed into the 
consumed amount of the parent substance (e.g. cocaine 
calculated from benzoylecgonine loads using specific 
correction factors) or they were converted into doses/
day/1 000 population. Moreover, it was observed that, in 
some cases, different conversion factors had been used 
to back-calculate the consumption of a substance, as 
discussed in Chapter 2. Because of the enormous 
potential of this approach to provide rapid, objective and 
up-to-date information on the use of illicit drugs at local, 
national and international scales, it is imperative that a 
best-practice protocol is adopted in order to improve the 
reliability and comparability of results.
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I Introduction
The term ‘new psychoactive substances’ refers to 
chemical entities that produce effects similar to those 
produced by illicit substances, but that are not directly 
controlled by international conventions (specifically, the 
1961 United Nations Single Convention on Narcotic 
Drugs and the 1971 United Nations Convention on 
Psychotropic Substances). These substances are often 
not newly developed from a scientific perspective, but 
are newly available as products on the (illicit) drugs 
market. To date, more than 450 such compounds have 
been reported to the EMCDDA, Europol and the 
European Medicines Agency (EMA) since the 
establishment of the ‘Action on new drugs’ via the 
Council of the European Union (Decision 2005/387/
JHA, May 2005) on the information exchange, risk 
assessment and control of new psychoactive 
substances (EMCDDA, 2015). However, the potential 
number of compounds that could fit into this category is 
limited by only the imagination of synthetic chemists and 
their ability to side-step legislation. The new 
psychoactive substance market is, in this respect, very 
dynamic and adaptation to changes in the legislation 
plays a role in these dynamics. During 2014, 101 new 
psychoactive substances were reported to the EU Early 
Warning System (EWS) for the first time.
The development, management and amendment of 
effective drug policies relies heavily on the availability of 
accurate and timely information on the drug situation. 
That is to say, information is required on exactly what 
drugs are being produced, transported and used (and in 
what quantities). In Europe, this information is acquired 
via key epidemiological indicators, such as general 
population surveys and demand for treatment, among 
others, and a range of drug market information sources. 
However, the difficulty with these indicators, in light of 
the new psychoactive substance situation, is that many 
users are unaware of exactly which substances they are 
using. For example, a survey respondent may admit to 
the use of ‘ecstasy’, which formerly would imply the use 
of MDMA, but now could, in fact, imply that they have 
used one (or several) of any number of synthetic 
phenethylamines, or indeed another class of 
psychotropic substances.
Analysis of wastewater has been proposed as a tool for 
providing useful information on temporal and regional 
trends in the use of new psychoactive substances, 
because this technique can potentially provide accurate 
information on the identity and quantity of the drugs 
being used at any given time (Reid et al., 2014). While 
this technique has proved successful with regard to 
assessing the use of established illicit drugs, such as 
cocaine and amphetamines (Thomas et al., 2012; Ort et 
al., 2014), the new psychoactive substance market 
presents a number of challenges and, therefore, 
alternative solutions, using altered sampling and 
analysis methodology (as opposed to standard methods 
of wastewater analysis, as described in Chapters 1 and 
2), may be necessary. The challenges include the 
following: the large number of individual substances on 
the market; the dynamics of the market and the rapidity 
at which ‘old’ drugs are substituted with ‘new’ 
alternatives; the relatively small size of the new 
psychoactive substance market with respect to the illicit 
drug market (e.g. the size of the synthetic cannabinoid 
market in Norway is relatively small when compared with 
the market for cannabis products; see Figure 4.1); and 
the lack of (clinical) data from rigorous pharmacokinetic 
profiling studies that provide the information necessary 
to identify and determine the rates of excretion of these 
drugs and their metabolites.
The last two challenges in this list relate to the 
selection of suitable, specific chemical substances that 
can be measured in wastewater and used as 
‘biomarkers’ of drug use. The analysis of wastewater for 
drug epidemiology is essentially an extension of the 
toxicological analysis of urine, so the chosen 
biomarkers in wastewater analysis are generally the 
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3)  a shift from the targeted analysis of selected known 
drug residues (as is common for the analysis of 
‘classical’ drugs) to suspect screening (Chiaia-
Hernandez et al., 2014) and retrospective analysis of 
data acquired from non-targeted (or unbiased) 
analytical methodologies where little or no 
knowledge is available on which exact chemical 
species (drugs or metabolites) may be present when 
the initial wastewater sample is collected, processed 
and analysed.
These necessary adjustments in approach will affect the 
way in which the obtained results are interpreted and 
used in drug monitoring.
I  Identification and selection of appropriate new psychoactive substance biomarkers by computer modelling
New psychoactive substances encountered by 
healthcare services, law enforcement agencies 
(including customs authorities) and national medicines 
agencies are reported to the EMCDDA and Europol 
under the framework of the EU Early Warning System 
(EMCDDA, 2007). One of the critical outputs of this 
framework is the European database on new drugs 
(EDND), which presents up-to-date information on the 
occurrence of new psychoactive substances in the 
European Union (and individual Member States). This 
database is an excellent ‘spring-board’ for wastewater 
analysts, as it provides an up-to-date list of the 
compounds known to have been encountered on the 
drugs market in Europe. Substances on this list can then 
be passed through pharmacokinetic and 
physicochemical modelling to identify appropriate 
biomarkers that could subsequently be added to 
analytical databases.
Pharmacokinetic profiling involves reviewing the rates of 
absorption, distribution, metabolism and excretion of 
new psychoactive substances after administration (or 
use). Of particular importance to wastewater analysts 
and toxicologists alike are the metabolism and excretion 
partitions, because it is these two factors that play the 
most significant role in determining the identity and 
expected amount of a particular biomarker in urine (and 
thereby wastewater).
It is expected, however, that clinical and laboratory data 
on the pharmacokinetics of recently identified new 
psychoactive substance will be limited or non-existent; 
same as the well-established and well-understood 
urinary excretion products of target drugs used in 
toxicology. It follows that the requirements for 
biomarker suitability for wastewater analysis are the 
same as those for toxicology, that is that the analyte 
must be a specific marker of the target drug and not 
formed exogenously, it must be stable (chemically and 
enzymatically) within the sewer system, and it must be 
present at concentrations high enough to allow its 
detection and quantification. While information on 
these criteria is readily available for established illicit 
drugs, it is lacking (or completely absent) for many new 
psychoactive substances; therefore, alternative data 
sources are required.
The approaches proposed as potential solutions to the 
above challenges can be broadly divided into three 
groups:
1)  the use of computer-based modelling tools to predict 
the identity and fate of new psychoactive substance 
residues in urine and wastewater which will serve as 
a proxy for in vivo or in vitro studies in the laboratory;
2)  a shift from the analysis of wastewater from large, 
non-specific general populations to wastewater from 
more targeted populations in which the use of new 
psychoactive substances is expected (e.g. 
wastewater from nightclub toilets or festivals or 
similar);
FIGURE 4.1
The size of the synthetic cannabinoid market in Norway 
relative to cannabis products, as measured by the 
occurrence of National Criminal Investigation Service 
(NCIS) seizures 
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of a substituted phenethylamine, a synthetic opioid and 
an arylcyclohexylamine, respectively, are presented 
(Table 4.1). In these examples, the in silico predictions 
are in good agreement with the (albeit limited) literature. 
The next step in the process is to assess the stability and 
fate of these predicted biomarkers in wastewater. Drug 
residues are subject to a number of different processes 
as they are transported through wastewater networks to 
the point of sampling and eventual analysis (Baker and 
Kasprzyk-Hordern, 2011; Castiglioni et al., 2013; Plósz et 
al., 2013). The two main processes that can affect new 
psychoactive substance biomarkers during transit and 
sample handling and storage are transformation and 
sorption. The term ‘transformation’ refers to the 
therefore, the identification and selection of appropriate 
biomarkers will require alternative data sources, such as 
those generated by computer models (so-called in silico 
modelling). The SMARTCyp model was the first web-
based application to be developed to predict the 
metabolism of drugs via the cytochrome P450 family of 
enzymes (Rydberg et al., 2010a, b). SMARTCyp models 
drug reactivity and predicts the likelihood of metabolism 
of particular sites of a drug molecule by applying scores 
to each atom: a lower score implies a greater chance of 
metabolism. The tool has been used to successfully 
identify the urinary metabolites of MDMA, mephedrone, 
JWH-018 and MAM-2201 (Reid et al., 2014). In the 
current report, the results of an exercise carried out on 
25I-NBOMe, AH-7921 and methoxetamine, as examples 
TABLE 4.1
In silico prediction of metabolism, biodegradation and adsorption potentials for 25I-NBOMe, methoxetamine and 
AH-7921
25I-NBOMe Methoxetamine AH-7921
SMARTCyp scores (1) Metabolite
Atom 
number
Standard 2C9 2D6 Average
Putative 
metabolism
Identified 
in literature
Log P
Biodegradation 
potential (%) (2)
Adsorption 
potential 
(%) (3)
25I-NBOMe 17 52 60 66 59 O-demethylation Stellpflug et 
al., 2014
3.18 0 41
1 52 60 80 64 O-demethylation Stellpflug et 
al., 2014
2.69 0 41
23 52 66 80 66 O-demethylation Stellpflug et 
al., 2014
3.53 0 41
Methoxetamine 2 33 46 94 58 N-dealkylation Meyer et al., 
2013
2.15 48 1
17 52 60 73 61 O-demethylation Meyer et al., 
2013
2.61 29 3
8 52 65 99 72 Acetylation Meyer et al., 
2013
1.99 6 24
AH-7921 1, 3 32 45 93 56 N-dealkylation Vorce et al., 
2014
3.61 2 35
19 66 74 101 81 Hydroxylation 2.61 1 5
18 67 81 115 88 Hydroxylation 2.54 1 5
(1) Calculated via www.farma.ku.dk/smartcyp. Only the best (lowest) three scores for each new psychoactive substance are displayed.
(2) Non-linear MITI (Ministry of International Trade and Industry) Biodegradation Model (BIOWIN 6, U.S. Environmental Protection Agency, USA).
(3) EPISuite (U.S. Environmental Protection Agency, USA): WWTPWIN sludge adsorption potential based on BIOWIN 6-derived half-lives.
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psychoactive substances. In general, the best that can 
be expected from these models is that they produce a 
concise list of ‘possible’ sewage biomarkers for new 
psychoactive substance use, and provide a warning if 
one or more of these biomarkers is expected to be 
unstable in wastewater. Confirmation of these 
predictions would be reliant on the use of laboratory-
based experiments such as human-liver microsome 
incubations (for in-vitro metabolism) and biodegradation 
studies.
I  Utility of targeted or site-specific sampling
While the use of new psychoactive substances appears 
to be an expanding problem and there is a very large 
number of drugs (or substances) that fall under this 
definition, it is difficult to describe the exact size of the 
new psychoactive substance market in relation to that of 
the established illicit drug market. The large number of 
these substances does, however, imply that the market 
is diverse and that the total use of any one particular 
new psychoactive substance is likely to be low compared 
with that of an established illicit drug (see Figure 4.1 for 
an example of synthetic cannabinoid use in relation to 
cannabis product use in Norway). This characteristic 
gives rise to a very significant challenge for wastewater 
analysis in that the measurable concentration (or 
amount) of a particular new psychoactive substance 
biomarker is expected to be low. A possible solution to 
this problem is to move away from sampling large-scale 
municipal wastewater towards the sampling of 
wastewater from targeted populations that are expected 
to have higher use levels of new psychoactive 
substances than the general population and, therefore, 
will produce higher measureable concentrations of 
biomarkers in wastewater. The analysis of pooled urine 
wastewater from portable public urinals (pissoirs) 
achieves this objective in two ways: firstly, pissoirs can 
be placed in areas in which target populations are 
expected to congregate or in which the use of new 
psychoactive substances is expected (e.g. at music 
festivals) and, secondly, urine from portable toilets is 
less dilute than urine from municipal wastewater 
systems because dilution occurs in municipal 
wastewater as a result of the domestic use of water 
(showers, washing machines, etc.) and the infiltration of 
rain water. The concentrations of new psychoactive 
substance biomarkers in pissoir-derived wastewater are, 
therefore, expected to be orders of magnitude higher 
than those in municipal wastewater, which will increase 
the likelihood of detection.
degradation or metabolism of a biomarker that results in 
a reduction in the concentration of that marker in 
wastewater. This loss or reduction would, in turn, lead to 
artificially low estimates of drug consumption or, indeed, 
false negatives if it is not appropriately accounted for. 
Transformation can also refer to the formation of the 
biomarker by chemical or enzymatic processes in the 
sewer system, which would lead to artificially high 
estimates of drug consumption. Transformation in 
wastewater is determined by the same phases (phases I 
and II) as drug metabolism in the human body; the 
enzymatically mediated processes associated with the 
cytochrome P450 family of enzymes, peroxidases and 
esterases are not exclusive to the human body and these 
enzymes are also involved in the transformation of new 
psychoactive substance biomarkers in wastewater 
(Plósz et al., 2013).
Adsorption is the process whereby new psychoactive 
substance biomarkers bind to solid particulate matter or 
surfaces within the wastewater system. Such processes 
are governed by a number of physicochemical properties 
of the given chemical (biomarker), but, in general, the 
most important features are surface energy and 
lipophilicity (as measured by log P or log D).
As with pharmacokinetic prediction, there are a number 
of in silico tools that can be used to predict and identify 
whether or not transformation and adsorption are likely 
to be a concern for analysts working on new 
psychoactive substances in wastewater (Reid et al., 
2014). Table 4.1 presents the results of applying these 
models to the predicted metabolites of new 
psychoactive substances. The predicted metabolites of 
25I-NBOMe and AH-7921 are likely to be stable in 
wastewater (biodegradation potential of < 5 %), but 
adsorption to particulate matter is a potential concern 
for 25I-NBOMe (adsorption of 41 %). The predicted 
dealkylation metabolites of methoxetamine are expected 
to be unstable in wastewater, as the biodegradation 
potential for both of these metabolites is in the 25–50 % 
range, which indicates that they are less stable than 
cocaine (a biodegradation potential of 21 % was 
determined using the same model).
The major limitation associated with the use of in silico 
models is that the results are (by definition) just 
predictions of what may occur, and this by no means 
guarantees that the results are accurate. The SMARTCyp 
model, for example, is reported to have a 76 % success 
rate (Rydberg et al., 2010b). Likewise, the BIOWIN-6 
biodegradation model used in Table 4.1 is derived from a 
dataset of 884 chemicals (Tunkel et al., 2000), and these 
substances may not always have physicochemical 
properties that are adequate proxies for new 
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A number of studies have shown that analyses of pooled 
urine samples from city centre, nightclub and music 
festival toilets allows the identification of new 
psychoactive substances, thereby providing timely data 
on exactly which drugs are currently in use at a particular 
location or within a particular population (Archer et al., 
2013a, b, 2014; Table 4.2).
I  Utility of unbiased data acquisition and (retrospective) analysis
The analysis of established illicit drugs in blood, urine 
and wastewater is based on the detection and 
quantification of a parent drug or well-documented 
metabolites of this drug, and the methods for sample 
preparation, extraction and detection can be developed 
and validated in advance (Figure 4.2). With new 
psychoactive substances, however, the identity of the 
biomarkers is not always known and, therefore, methods 
must be developed to allow the detection of all 
compounds in a sample without prior knowledge of what 
the eventual target compound is likely to be. Within this 
paradigm (Figure 4.2), an analyst will perform unbiased 
data acquisition and, at a later stage, will investigate the 
TABLE 4.2
Summary of new psychoactive substances identified in pooled urine samples
New pychocative substance Sample type Reference
Mephedrone
Nightclub urinal, London (2011) Archer et al., 2013a3-Trifluoromethylphenylpiperazine
2-AI (2-aminoindane)
Cathine
City centre urinals, London (2012) Archer et al., 2013b
Methylhexaneamine
4-Methyl methcathinone
Methiopropamine
Methoxetamine
4-Methyl methcathinone
City centre urinals, London (2012) Archer et al., 2014
Methylhexaneamine
Methcathinone
4-Ethylmethcathinone
Methiopropamine
Pipradrol
Cathinone
5-(2-Aminopropyl)benzofuran
1,4-Trifluoromethylphenylpiperazine
4-Methylbuphedrone
4-Methylethcathinone
1,4-Methoxyphenylpiperazine
4-Fluoroephedrine
1-(2-methoxyphenyl)piperazine Pooled portable toilet, Oslo (2013) Reid et al., 2014
collected data by searching for specific drugs or 
biomarkers within an electronic record (Ibáñez et al., 
2014; Reid et al., 2014). A suitable analogy would be a 
photographer taking a high-definition digital photograph 
then later analysing that picture for specific colours; for 
the purpose of detecting a new psychoactive substance 
in wastewater (or urine), the ‘camera’ is a high-resolution 
mass spectrometer.
In the example shown in Figure 4.3, 2 786 individual 
chemical species (represented by coloured dots) were 
identified by high-resolution mass spectrometry of a 
single sample of pissoir-derived wastewater. The 
high-resolution mass spectrometry data that were 
recorded and stored for each of the 2 786 compounds 
identified include data on chromatographic retention 
times, exact mass and isotopic abundance; from these 
data, a nominal chemical formula can be derived. This 
record can be filed and then later screened for the 
presence of any given new psychoactive substance (or 
associated biomarker). Filtering this extensive high-
resolution mass spectrometry data record for target new 
psychoactive substance biomarkers is aided by the fact 
that many new psychoactive substances share 
structural elements or moieties. This allows for common-
fragment and mass-defect filtering to be performed on 
the high-resolution mass spectrometry data, thereby 
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Warning System or predicted by in-silico modelling in the 
future. This technique therefore allows the rapid and 
comprehensive screening of complex samples for 
biomarkers of specific new psychoactive substances 
without the need for prior development and validation of 
specific analytical methods.
High-resolution mass spectrometry also allows the later 
processing, detection and tentative confirmation of the 
presence of a compound without the need for a 
standard reference compound. The screening of 
samples with the aid of a reference library of new 
psychoactive substance spectra and retention indices in 
a database is a possibility, with the potential to add new 
compounds as they are identified. There is also the 
potential for retrospective analysis, that is 
re-investigation of previously analysed samples if 
additions are made to the database.
I  Utility of new psychoactive substance screening results
The analysis of the residues of illicit drugs (such as 
cocaine, cannabis and amphetamines) in municipal 
wastewater provides quantitative data which can be 
used to back-calculate the total amount of a drug used 
by the general population. These data are particularly 
useful for regional comparisons on drug consumption 
and the eventual generation of time-series, which allow 
the study of changes in drug use over time (Table 4.3).
The screening of new psychoactive substances in 
wastewater will not, unfortunately, be able to generate 
the same level of data as can be generated for 
established illicit drugs, particularly in the early stages 
of use of a new psychoactive substance. This is 
because the methods used for the back-calculation of 
FIGURE 4.2
Flow charts for the targeted analysis normally carried 
out for established illicit drugs, and for the retrospective 
analysis paradigm required for new psychoactive 
substance screening
Targeted
 analysis
Established illicit drugs
Select suitable 
biomarker
Develop and 
validate an analysis
method for the
chosen biomarker
Collect samples
Analyse samples
for the chosen
biomarker
Process and 
report data
Retrospective 
non-biased analysis 
New psychoactive substances
Collect samples
Analyse samples
and store raw data
Identify new 
psychoactive 
substances
Run in-silico models
to predict biomarkers
Run in-silico models
to predict suitability
of biomarkers
(stability etc.)
Select suitable
biomarker
Screen raw data 
for biomarker
Process and 
report data
TABLE 4.3
The utility of the analysis of drug biomarkers in 
wastewater
Established illicit drugs in 
municipal wastewater
Early new psychoactive 
substance screening in 
pissoir-sourced wastewater
Targeted analysis on pre-
selected and validated 
biomarkers
Quantitative results
Back-calculated use data 
(quantity/volume)
Generation of time-series and 
regional comparisons
Retrospective analysis on in 
silico predicted biomarkers
Non-quantitative results
Time-series and regional 
comparison by frequency of 
detection
focusing the search on little-known chemical species 
and making it more manageable. This filtering approach 
is illustrated in Figure 4.3: only 475 species (of the total 
2 786) remain after mass-defect filtering around 
AH-7921 and, of the 475 retained species, only one has a 
chlorine isotope pattern that implies that it could be 
related to AH-7921, and none has a 
dichlorobenzaldehyde moiety (associated with a mass 
spectral fragment with mass to charge ratio of 172.955), 
as expected for AH-7921 and related metabolites (Vorce 
et al., 2014).
In this example, neither AH-7921 nor any probable 
related metabolites were found to be present, but it is 
possible that other new psychoactive substance 
residues are present in the sample. This sample and the 
associated high-resolution mass spectrometry data 
record could be investigated again if another new 
psychoactive substance is identified by the Early 
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Data derived from screening new psychoactive 
substances in pissoir-sourced wastewater are mostly 
qualitative, but there are certainly significant 
opportunities for building semi-quantitative datasets 
(Table 4.3). The generation of time-series and the 
eventual comparison of data from differing populations 
could be based on frequency. In this way, the measured 
value is not a drug consumption estimate, but instead 
the frequency at which a particular new psychoactive 
substance is detected. In addition, if levels of use of a 
new psychoactive substance are sufficiently high among 
the general population that appropriate biomarkers are 
detectable in municipal wastewater, it will be possible to 
generate time-series data and run population-based 
comparisons on the biomarker itself. Although analysts 
may not be able to give precise estimates of the amount 
of new psychoactive substances used, they will be able 
to provide details on how much the use has changed 
over time and how this relates to use in other 
populations.
I Conclusions
The new psychoactive substance market presents a 
unique set of challenges to all drug epidemiologists, 
including those working with wastewater, because this 
drug use are reliant on the availability of well-
documented excretion ratios, which describe the 
percentage of the initial drug dose that is excreted in 
urine as a particular biomarker. Few or no clinical trial 
data are available on the excretion ratios of the most 
recently identified new psychoactive substances so it is 
not possible to quantitatively relate measured 
biomarker concentrations in wastewater to absolute 
estimates of new psychoactive substance 
consumption. Back-calculation methods are also reliant 
on accurate measurements of sewage volume as these 
provide the key link between measured drug biomarker 
concentrations and calculated drug loads. The 
screening of new psychoactive substances in pissoir-
sourced wastewater does not provide the same 
opportunity because volume measurements are often 
not available, and do not necessarily have any 
correlation with the total daily urine volume of a target 
population.
It is important to note that the representability of the 
population visiting an event may be limited because a 
percentage of the attendees will not make use of a 
pissoir, and indeed the availability of urine from pissoirs 
at an event cannot always be guaranteed because of 
privacy regulations, or because festival organisers or 
club managers do not wish to be stigmatised.
FIGURE 4.3
Mass defect plot for a sample of pissoir-derived wastewater
NB: The plot shows a total of 2 786 individual chemical species (coloured dots) with molecular weights in the range of 90–800 Da. The target new 
psychoactive substance (in this case AH-7921) is highlighted in red. A total of 475 species (blue) pass the filter (green area) on the mass defect 
associated with AH-7921 (50 mDa tolerance around a defect of 118 mDa).
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market is extremely dynamic and new compounds are 
being introduced at a rapid rate. The lack of experimental 
data on pharmacokinetics and unanswered questions 
related to biotransformation pathways severely impede 
the identification, detection and quantification of these 
new psychoactive compounds in samples of wastewater. 
There are, however, a number of in-silico-based tools 
that can be used to predict these unknown parameters 
and provide a concise list of potential biomarker targets. 
It should be noted, however, that by no means do these 
models guarantee the formation of a given metabolite or 
biotransformation product; therefore, extensive non-
targeted screening by retrospective analysis of high-
resolution mass spectrometry data will be required.
Screening for potential biomarkers of new psychoactive 
substances by high-resolution mass spectrometry provides 
the ability to detect and (tentatively) confirm the presence 
of a compound without the need for standard reference 
material, and the fact that many new psychoactive 
substances share structural elements also allows 
common-fragment searches and mass-defect filtering to 
be performed. These techniques focus the search on 
unknown metabolites and reduce spectral noise, leaving 
only the information that is most likely to be related to a 
series of new psychoactive substance biomarkers.
The concentrations of new psychoactive substance 
residues in wastewater are often below the lower limit of 
detection; therefore, the collection and analysis of 
wastewater from pissoirs has, thus far, been used as a 
relatively successful alternative to municipal wastewater. 
This technique may be the primary alternative for new 
psychoactive substance detection, but it is important to 
remember that pissoir-derived screening exercises 
provide data that are more qualitative than quantitative 
in nature and comparisons between regions or over time 
will most likely be based on frequency of new 
psychoactive substance detection rather than on the 
magnitude of consumption.
In summary, the combination of these tools and 
alternative data sources provides an excellent 
framework in which to maximise the likelihood of 
successfully identifying and detecting biomarkers for 
new psychoactive substances in wastewater, albeit with 
differing interpretation outcomes.
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I Introduction
Wastewater-based epidemiology can provide near-real-
time estimates of drug use within a defined population 
and can track changes in drug use over time. This 
information is complementary to that available from 
established drug-use monitoring methods. Realising the 
full potential of wastewater-based information will 
depend on integrating it into the existing set of 
epidemiological indicators. In Europe, our knowledge of 
drug use is built on the findings of a range of 
epidemiological indicators. Surveys of the general and 
school populations provide the ‘big picture’ on the use of 
drugs at national and European level. Data collected on 
users entering treatment are a vital source of information 
on the more risky forms of drug use, and this is 
supplemented by data gathered through special studies, 
using methods designed to sample hard-to-reach 
populations and stigmatised behaviours. Further 
indicators report on the harms associated with drug use, 
such as drug-related diseases and deaths. In addition, 
monitoring of drug market (price, purity, seizures) and 
drug-related crime indicators allows a comprehensive 
overview of the drug situation.
How wastewater analysis can fit into the monitoring of 
drug use has been addressed by Castiglioni et al. (2014), 
who looked at how epidemiological approaches based 
on wastewater analysis and surveys compare and can 
complement each other (Table 5.1).
To date, few attempts have been made to compare the 
drug use estimates obtained through wastewater 
analysis and epidemiological surveys. Although 
complicated and fraught with difficulties and limitations, 
the comparison of these different approaches provides 
CHAPTER 5
Integrating wastewater analysis with 
conventional approaches for 
measuring illicit drug use
Sara Castiglioni, Ettore Zuccato, Kevin Thomas and Malcolm Reid
TABLE 5.1
Summary of the main features of established epidemiological approaches and wastewater-based epidemiology
Information provided
Drug epidemiology  
(established approaches)
Wastewater-based epidemiology 
(wastewater analysis)
Methods employed to estimate drug use
High costs of studies Yes a No
Real-time estimates No Yes
Retrospective analysis No Yes
Drug use estimates
Frequency and patterns of drug use Yes No
Changes in population levels of drug use in a short time period 
(daily, weekly, annual)
No Yes
Mode of drug use Yes Yes/no b
Main groups of users Yes No
Purity of drugs Yes No
Emerging trends in drug use (e.g. appearance of new drugs) No/not systematic c Yes
(a) Except for cases in which routinely available data were analysed.
(b) Subject to the availability of characteristic biomarkers.
(c) Only in specifically targeted surveys or studies.
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0.7 % (range 0.36–1.03 %) of drivers tested positive 
for cocaine use.
3)  Cocaine metabolites in wastewater from a sewage 
network that processed waste from 570 000 
inhabitants were analysed. The results from samples 
collected throughout September 2009 provided an 
estimated combined cocaine consumption rate of 
1 458 g (of pure cocaine) per week (range of 1 158–
1 758 g/week).
The study methods, results and conclusions are covered 
in detail in the original published text (Reid et al., 2012). 
Therefore, in the present report, only a synopsis of a case 
study is provided in which one attempt at integrating 
wastewater analysis with established drug use 
measures is described.
I Methods of comparison
Comparing consumption estimates
Total population cocaine use was estimated from the 
general population survey dataset via a ‘bottom-up’ 
method, in which the number of users is multiplied by 
the reported frequency of use and the reported amount 
(mass) of cocaine used. This is then directly comparable 
with the wastewater-based estimate. No consumption 
estimate was derived from the survey of drivers.
Comparing prevalence estimates
Wastewater analysis provides only a direct measure of 
the total amount of cocaine used within a population; 
therefore, any attempt to estimate the prevalence of use 
from these data must be derived from per-user 
consumption figures. More specifically, the number of 
users in a population is calculated by dividing the total 
consumption of the population (in g per year) by the 
estimated per-user consumption amount (9.8 g/year per 
user) from the general population survey dataset.
The general population surveys and the roadside survey 
deliver prevalence estimates, but with differing 
timeframes. General population surveys generally 
involve questions related to use within the last 6 to 12 
months, while the analysis of oral fluid (as carried out in 
the roadside survey) has a cocaine-detection window of 
less than 24 hours. The comparison of these datasets, 
therefore, requires a timeframe adjustment. The general 
population survey data include self-reported frequency-
of-use statistics, so it is possible to derive a statistical 
probability of use for the last 24 hours which is directly 
comparable with the driver survey. For instance, on this 
the possibility to indirectly check quality and accuracy, 
since they approach the challenge from different 
viewpoints and, together, can provide a better 
assessment of drug use in a specific community than 
either could alone. In the current chapter, some of the 
first attempts to compare results obtained from these 
two approaches, with regard to cocaine use, are 
presented and discussed, and the limitations and 
requirements for further research in this field are 
highlighted. The first study of this type, performed in 
Oslo, Norway, compared the results from three different 
datasets, two obtained by population surveys and one by 
wastewater-based epidemiology. The second study 
analysed the temporal and spatial trends of cocaine use 
in Italy as estimated by wastewater-based epidemiology, 
and compared these results with those obtained from 
local and national epidemiological surveys undertaken 
during the same period.
I Norwegian case study
I Introduction
In an attempt to understand how data from wastewater 
analysis can be used in an epidemiological context and 
to determine how these data can be integrated with 
more established epidemiological methods, Reid et al. 
(2012) carried out an analysis on data describing the use 
of cocaine in Oslo, Norway. The analysis was designed 
around the seemingly simple task of comparing the 
results of three distinct datasets with the aim of 
identifying how they align and, most importantly, where 
additional information is needed.
Three distinct datasets from three different sources 
formed the basis of this analysis:
1)  A set of regional general population surveys were 
carried out between 2000 and 2010 and included a 
total of 14 438 respondents. In this dataset, the 
annual prevalence of cocaine use by the population, 
aged 15–64 years, was 2.9 % (range 2.6–3.2 %). 
More than 50 % of users in the general population 
reported using the drug on between one and four 
occasions in the 6 months preceding the survey, 
while less than 5 % reported daily or almost daily 
use. Self-reported per-user cocaine consumption 
rates were, on average, 9.8 g (of pure cocaine) per 
user per year.
2)  A sample survey of drug use among drivers (roadside 
survey) was conducted between 2008 and 2009 and 
included a total of 2 341 respondents. The analysis of 
oral fluid for cocaine and metabolites showed that 
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on limited published data and self-reported use in a small 
sample of the Norwegian user population, but there were 
no direct measurements made of the weight or purity of 
the drug used, which could have been used to validate the 
results. Further work has since been carried out in an 
attempt to arrive at a more reliable estimate of per-user 
cocaine use (Amundsen and Reid, 2014) and, while the 
results of this later study agree (for the most part) with 
the initial estimate, there were still no measurements of 
weight or purity which could be used to support the 
findings. A positive outcome of this study is that, because 
per-user consumption is a common denominator for both 
general population survey prevalence and wastewater-
derived mass measurements, these two datasets could 
be combined to triangulate a more accurate per-user 
consumption figure in the future.
The validity of the sample populations was also 
highlighted as a confounding factor within this 
comparison. Inconsistencies between the sample 
populations, from which each of the three datasets were 
derived, arise from both temporal and spatial 
incompatibilities. Temporal inconsistencies arise 
because the general population survey dataset 
combines results from numerous surveys conducted 
over more than a decade, while the wastewater 
measurements that form the basis of the comparison 
were carried out over the course of only a single month 
in 2009. This study would best be conducted on data 
from a single year (2009), but the volume of data 
available from a single year is low, so additional data 
from multiple years were used with the knowledge that 
cocaine consumption in Norway has been relatively 
stable over the last decade.
Inconsistencies in the spatial domain are apparent 
because the population is mobile. This affects 
wastewater data, as it is possible for people to move in 
and out of the sewage catchment throughout the course 
of a day, but it is, of course, the driver population that is 
most susceptible to such error because this population 
is highly mobile. However, perhaps the largest 
unanswered question with regard to the roadside survey 
is how the driver population and the cocaine user 
population are aligned. It was somewhat surprising to 
see that the survey of the driver population showed the 
highest prevalence rates of cocaine use and, although it 
is entirely possible that cocaine use is indeed higher in 
the driver population, no formal conclusions can be 
made in this regard without first repeating the general 
population survey with specific questions related to the 
use of motor vehicles.
The numerous difficulties and shortfalls reported by Reid 
et al. (2012) highlight the fact that wastewater methods in 
basis, a person reporting having used the drug on 18 use 
days in the last 6 months (i.e. about 180 days) would be 
assumed to have a 10 % probability of using cocaine on 
any given day.
I Results of the original analysis
Comparing consumption estimates
Applying a bottom-up approach to the general 
population survey dataset provided a combined annual 
consumption estimate for the total population of 117 kg 
per year (range of 70–165 kg/year). This is comparable 
to the wastewater estimate of 76 kg per year (range of 
60–91 kg/year).
Comparing prevalence estimates
The data from the combined general population survey 
revealed a last 12-month prevalence of 2.9 % (2.6–
3.2 %), whereas a prevalence rate of 1.9 % (1.0–4.0 %) 
was derived from a combination of wastewater-sourced 
total population consumption data and self-reported per-
user consumption data.
By adjusting the timescale of the last 12 month 
prevalence data, a 24-hour prevalence figure, that can be 
directly compared with data from the roadside survey, 
was derived. The roadside survey showed that 0.7 % 
(0.36–1.03 %) of the drivers tested positive (weighted 
for undersampling/oversampling relative to the general 
population; Reid et al., 2012) for cocaine use, whereas 
the prevalence rate derived from the general population 
survey was 0.22 % per day (0.13–0.30 %/day).
I Discussion and conclusions
Reid et al. (2012) carried out the study described above 
in order to better understand how data from wastewater 
analysis can be used in an epidemiological context, and 
to determine how these data can be integrated with data 
from epidemiological surveys. Comparing the three 
datasets was not a trivial exercise because there is little 
published data on per-user cocaine consumption, and 
because the extent of overlap of these three study 
populations is unknown.
Per-user consumption estimates are the only means by 
which the wastewater-derived total population 
consumption can be directly compared with prevalence 
estimates. Reid et al. (2012) made some general 
assumptions with regard to per-user consumption, based 
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results obtained were compared with profiles 
obtained by population surveys.
I Methods
Wastewater analysis
In the first study, 24-hour composite samples of 
wastewater were collected from the inlet to the principal 
wastewater treatment plant in Milan (Milano-Nosedo) by 
sampling wastewater every 20 minutes for 24 hours. 
Samples were taken daily, on consecutive days in 
November 2005 (7 days), March 2006 (16 days), March 
to April 2008 (35 days), and again in March (30 days) 
and September 2009 (7 days). Samples were analysed 
by liquid chromatography–mass spectrometry for 
cocaine metabolites (Castiglioni et al., 2011) and 
cocaine consumption was estimated by back-calculation 
from benzoylecgonine loads, as described elsewhere 
(Zuccato et al., 2005).
In the second study, wastewater samples were collected 
on 7 consecutive days from the wastewater treatment 
plants of 17 cities in Italy (six in northern, four in central 
and seven in southern Italy) in October 2011. Samples 
were collected and processed, as described above, to 
estimate cocaine consumption in the cities under study.
Population surveys
Survey data were extracted from published reports. The 
last month and last year prevalences of cocaine use in 
Milan in 2007 and in 2010 were obtained from a 2011 
report on the consumption of psychotropic substances 
in Milan (ASL Milano, 2011). The last year prevalence 
data for cocaine use in Italy in 2008 and 2010 were 
obtained from the National Drug Policy Department’s 
2010 national report to parliament (DPA, 2010), while 
the 2012 last year prevalence data for northern, central 
and southern Italy were extracted from the 2012 
national report (DPA, 2012).
Comparison
In the first study, the estimates of cocaine consumption in 
Milan for 2008 and 2009, as assessed by wastewater 
analysis, were compared with the prevalence of use in 
Milan (last month prevalence for 2007 and 2010) and in 
Italy as a whole (last year prevalence for 2008 and 2010). 
In the second study, the consumption of cocaine, as 
estimated by wastewater analysis in 17 cities in Italy in 
October 2011 and pooled according to their geographical 
drug epidemiology cannot (in their current form) be used 
alone as a replacement for more survey-based indicators. 
Wastewater analyses generate only total community-wide 
consumption figures (amount of a drug used), which are 
difficult to compare with prevalence estimates without a 
wealth of supporting information. Wastewater analysis is 
best used as a source of supporting information to 
validate or confirm trends identified by the other 
indicators. For example, indications of a rise in drug use 
prevalence or demand for treatment services may be 
validated with supporting information from wastewater 
analysis. Data from wastewater analysis and data from 
other indicators are not expected to be in exact 
agreement, and a degree of overlap should be sufficient. 
Although a ‘snapshot’ in time and space might be difficult 
to obtain because of the lack of detailed information and 
inaccuracies in the precise estimation of consumption 
patterns and levels, a promising way of resolving these 
difficulties is to determine the congruence of wastewater 
and conventional indicators with regard to temporal and 
spatial patterns of use. Such validation of the use of 
wastewater-derived data as supporting information will, of 
course, require the more formalised collection of 
wastewater data at both the national and international 
level.
I Italian case study
I Introduction
The results from population surveys and wastewater 
analysis are difficult to compare, as the former is 
designed to estimate the prevalence of use and the 
latter to estimate the collective consumption of pure 
substances within a community. However, prevalence 
and consumption can be considered as two different 
measures of the same phenomenon and it is, therefore, 
important to verify whether or not these approaches 
produce convergent outcomes. To study this issue, we 
investigated the profiles and monitored the temporal and 
spatial trends of drug use by these two methods. In this 
case study, we compared the results obtained by the 
following consumption and prevalence studies:
1)  Temporal trends of cocaine use in Milan: cocaine use 
was monitored through wastewater analysis in Milan 
between 2005 and 2010. The consumption trends 
identified were compared with the outcomes of 
population surveys carried out in the same period in 
Milan and in Italy as a whole.
2)  Spatial distribution of cocaine use in Italy: cocaine 
consumption was studied in northern, central and 
southern Italy in 2011 by wastewater analysis. The 
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Spatial distribution of cocaine use in Italy
Cocaine estimates for October 2011, pooled according to 
the geographical location of the 17 cities investigated, 
showed that there was a significantly higher use of 
cocaine in central than in northern or southern Italy 
(p < 0.01). Population studies carried out at the beginning 
of 2012, which investigated cocaine use prevalence in the 
previous year, showed a similar distribution, with a greater 
prevalence of cocaine use in central Italy than in northern 
or southern Italy (Table 5.2).
I Discussion and conclusions
Because of the different types of information provided by 
wastewater analysis (collective consumption of pure 
substances within a community) and population surveys 
(prevalence in the last month or year), a direct comparison 
of the data is difficult. It was only possible to compare the 
distribution of cocaine use, that is, the temporal trends of 
cocaine use at a local level (Milan, northern Italy) and the 
spatial pattern of use in Italy as a whole.
The spatial distribution of cocaine consumption in Italy 
(northern, central and southern Italy) revealed by 
wastewater analysis was in agreement with the prevalence 
findings from population surveys. Similar results were also 
obtained in a recent study aimed at quantifying spatial 
differences and temporal changes in the consumption of 
illicit drugs across European regions (Ort et al., 2014). A 
clear spatial difference in illicit drug use across Europe was 
demonstrated, with cocaine use being highest in western 
Europe and methamphetamine use being highest in 
northern Europe, the Czech Republic and Slovakia; these 
results were in agreement with available survey data.
The decrease in cocaine consumption observed in Milan 
between 2008 and 2009 (45 % decrease), as determined 
location in northern, central or southern Italy, were 
compared with 2012 prevalence data extracted from the 
national report (Dipartimento Politiche Antidroga, 2012).
I Results
Time trends of cocaine use in Milan
Daily cocaine consumption levels, as estimated by 
wastewater analysis, in Milan were the same in 
November 2005, in March 2006 and March/April 2008, 
but fell by 45 % in March 2009 and remained at the 
same level in September 2009 (as determined by 
analysis of variance [ANOVA], p < 0.001; followed by 
Tukey–Kramer HSD [honest significant difference] test, 
p < 0.05; Zuccato et al., 2011). Further analysis 
performed in May 2010 showed that the use of cocaine 
in Milan remained stable (Figure 5.1).
Population surveys also showed a parallel drop in last 
month (from 2.6 % in 2007 to 1.2 % in 2010, i.e. a 
decrease of 54 %) and last year (from 5.0 % in 2007 to 
2.1 % in 2010, i.e. a decrease of 58 %) prevalence rates 
for cocaine use in Milan from 2007 to 2010 (ASL Milano, 
2011), and in the last year prevalence rates (from 2.1 % 
in 2008 to 0.9 % in 2010, i.e. a decrease of 57 %) in the 
general population in Italy (DPA, 2010).
FIGURE 5.1
Daily cocaine consumption, as estimated by wastewater 
analysis, in Milan
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NB: Study covers the catchment area of the Milan-Nosedo treatment 
plant. The results given are for the mean ± standard deviation, *p < 0.001 
(ANOVA), followed by Tukey–Kramer HSD test (2009 vs. 2005–2008).
TABLE 5.2
Measures of cocaine use in Italy (northern, central and 
southern), as estimated by wastewater analysis and by 
population survey 
Geographical 
location
Wastewater 
analysis
Population survey
Consumption 
(g/day/1 000 
population)
Last year 
prevalence (%)
Northern Italy 0.44 ± 0.08 0.27
Central Italy 0.71 ± 0.11* 0.34
Southern Italy 0.45 ± 0.07 0.22
NB: Prevalence data refer to the population aged 15–64.
*p < 0.01.
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advantage of providing data within a short time (days to 
weeks from sampling) and could, therefore, act as a first 
‘alert’ tool in the identification of new trends in drug 
consumption or the use of new substances (see Chapter 
4 for new psychoactive substances). Results from 
wastewater analysis can therefore anticipate results 
from population surveys, as shown in the study 
conducted in Italy (Zuccato et al., 2011) and described 
above. Moreover, wastewater analysis can easily provide 
information about large populations and can be applied 
on different scales to obtain information for almost the 
entire population of a country. In this case, it is 
necessary that specific sampling campaigns are 
designed and a representative set of wastewater 
treatment plants are selected in order to allow the 
extrapolation of consumption figures to the entire 
country.
Some additional limitations, related to the comparison of 
these different approaches, are ascribable to the 
potential lack of geographic correspondence between 
wastewater catchments and epidemiological surveyed 
areas; to resolve this, data from many wastewater 
catchment areas may have to be combined for 
comparison. In fact, the catchment areas of urban 
wastewater treatment plants can sometimes be larger 
than a single city, and, in these cases, specific 
adjustments will be required. Another important 
limitation is the different timeframes of the two 
approaches: drug use surveys typically gather data on 
use over a range of time windows (last month, last year, 
lifetime), whereas wastewater campaigns are typically 
on the scale of weeks or months. 
Data from wastewater analysis and data from 
conventional epidemiological indicators are not 
expected to be in exact agreement, but a degree of 
overlap should exist and be sufficient to demonstrate the 
complementary character of these approaches, as 
demonstrated by the case studies presented above. 
These studies may be considered a reliable validation of 
the use of wastewater-based epidemiology as a novel 
indicator along with the existing, well-established 
multi-indicator system used to monitor drug use in 
Europe. If wastewater-based epidemiology is to be used 
to obtain supporting information, more standardised 
methods of wastewater data collection, at both national 
and international levels, will be required.
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Therefore, wastewater analysis is best used as a source 
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time trends and spatial differences of consumption; 
these types of data could be used to validate or confirm 
trends identified by the other epidemiological indicators. 
For example, epidemiological indications of a rise in 
prevalence or demand for treatment services could be 
validated with supporting information from wastewater 
analysis. Moreover, wastewater analysis has the 
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Monitoring illicit drug use is difficult because of the 
hidden and complex nature of drug-using behaviours. 
The potential of wastewater analysis as an approach to 
complement established monitoring tools in the drug 
use area has been demonstrated. It has some clear 
advantages over other approaches, as it is not subject 
to response and non-response bias and can better 
identify the true spectrum of drugs being consumed; 
this latter advantage is important as users are often 
unaware of the actual mix of substances they take. This 
tool also has the potential to provide near-real-time 
information on geographical and temporal trends, and 
to provide data representative of relatively large 
population sizes.
Wastewater-based epidemiology involves several 
consecutive steps that allow researchers to identify and 
quantify target metabolic residues of illicit drugs in raw 
wastewater, and back-calculate the amount of the 
corresponding illicit drugs consumed by the population 
served by a wastewater treatment plant. It offers an 
interesting and complementary means of obtaining data 
that can be used to monitor the quantities of illicit drugs 
used at a population level, but it cannot provide 
information on prevalence and frequency of use, the 
route of administration, the main classes of users or the 
purity of the drugs. Additional challenges arise from 
uncertainties associated with the sampling of 
wastewater, the behaviour of the selected biomarkers in 
the sewer, the reliability of interlaboratory analytical 
measurement, the different back-calculation methods 
used and the different approaches used to estimate the 
size of a population being tested.
To improve the credibility and scalability of such studies, 
data from different sources need to be more reliable and 
comparable. Notably, the first Europe-wide study, 
performed in 2011 by the Sewage analysis CORe group 
Europe (SCORE) network, provided a comprehensive 
insight into the uncertainties associated with all of the 
wastewater-based epidemiology procedures. As a result, 
this group established a best-practice protocol for 
sampling, sample handling, chemical analysis, back-
calculation procedures and data reporting. This protocol 
has been revised and updated during subsequent 
analytical campaigns in Europe (EMCDDA, 2015).
Wastewater-based epidemiology is considered to be a 
potent approach for monitoring patterns and trends of 
illicit drug use within a community. Since 2005, the 
approach has been applied in several countries 
worldwide. This worldwide application has demonstrated 
the potential of this approach with regard to monitoring 
the use of most of the main illicit drugs (cocaine, 
cannabis, amphetamine, methamphetamine and 
MDMA). These studies revealed geographical differences 
in drug use patterns, which were mostly consistent with 
data obtained by other approaches (as reported by 
EMCDDA and the United Nations Office on Drugs and 
Crime). Moreover, wastewater analysis has been proven 
to be able to detect local and temporal patterns of drug 
use, demonstrating its potential to provide information 
complementary to standard techniques.
In view of the main features of wastewater-based 
epidemiology, one direct and novel application of this 
approach is for the detection of the use of new 
psychoactive substances. While the technique has 
proved successful for established illicit drugs, the new 
psychoactive substance market presents a number of 
challenges which mean that alternative sampling and 
analysis methodology may be necessary. The challenges 
include the large number of individual substances on the 
market, the dynamics of the market, the relatively small 
size of the new psychoactive substance market and the 
lack of data from rigorous pharmacokinetic profiling. 
Thus, obtaining reliable estimates of new psychoactive 
substance use is not feasible at present. Three 
conceptual approaches for dealing with new 
psychoactive substances, using biomarkers in 
wastewater, are discussed in this report.
Some attempts have been made to compare drug use 
estimates obtained through wastewater analysis and 
epidemiological surveys. Comparing the different 
approaches provides the possibility for indirectly 
checking quality and accuracy, and of improving the 
assessment of drug use in a specific community. The 
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has the potential not only to provide estimates of a broad 
number of lifestyle factors that influence health (i.e. illicit 
drugs, alcohol, tobacco and the use of counterfeit 
medicines), but also to provide information about health 
and illness within a community. For instance, it could 
potentially give information about diet, diseases, health 
status and exposure to environmental and food 
contaminants. Some of these topics are now under 
investigation within a Marie Curie Initial Training Network 
project (SEWPROF) entitled ‘A new paradigm in drug 
use and human health risk assessment: sewage profiling 
at the community level’ (www.sewprof-itn.eu). The 
network links 16 leading European institutions from 12 
countries and combines European expertise in 
wastewater-based epidemiology and related areas.
To conclude, future directions for wastewater research 
include studies aimed at advancing the identification of 
drugs and their metabolites, and minimising the 
uncertainties related to sampling, measurement and 
back-calculation methods. Better integration of this 
novel methodology with existing epidemiological 
indicators will allow for a more holistic understanding of 
societal health. The first multi-approach studies suggest 
that wastewater analysis can predict results from 
population surveys. Closer collaboration between 
epidemiologists and legal authorities will improve the 
perception of the ‘true’ drug situation, and allow for a 
better evaluation of interventions. Finally, the ethical 
rules for wastewater-based epidemiology are yet to be 
established. Since the approach is non-invasive, and 
does not allow for identification of drug-using 
individuals, it does not give rise to any obvious ethical 
issues. However, thorough study design and cautious 
management of relationships with research partners 
(e.g. prisons or forensic authorities) may be needed to 
protect the anonymity of sample providers in the case of 
studies of small communities in order to prevent 
stigmatisation. Special care is also suggested with 
regard to ensuring accurate communication of results to 
the media. The field awaits the establishment of best 
practices, taking into consideration the ethical aspects 
of wastewater research.
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first attempts to compare results from the two 
approaches for cocaine use are discussed in this 
publication. The first study, performed in Oslo, Norway, 
compared the results from three different datasets, two 
of which were obtained by epidemiological surveys and 
one of which was obtained by wastewater-based 
epidemiology. The second study analysed the temporal 
and spatial trends of cocaine use in Italy using 
wastewater-based epidemiology and compared the 
results with those from local and national 
epidemiological surveys undertaken during the same 
period.
The numerous limitations associated with the 
comparability and interpretation of the results reported 
in these examples highlight the fact that wastewater 
methods for drug epidemiology cannot, at present, 
replace more established indicators, but they can be 
used as a complementary tool to provide useful and 
novel information. Wastewater analysis is best used as a 
source of supporting information for population studies, 
for example, to assess the extent and rank of use of 
different substances and to gain information on patterns 
of use, including time trends and spatial differences in 
consumption; these types of data could be used to 
validate or confirm trends identified by the other 
epidemiological indicators. Moreover, wastewater 
analysis has the important advantage of being able to 
provide data within a short time (days to weeks from 
sampling) and for a relatively large part of the population; 
therefore, wastewater-based epidemiology could be 
used as a first ‘alert’ tool in the identification of new 
trends in drug consumption or the use of new 
substances.
The potential for wastewater-based epidemiology to be 
used in the evaluation of the effectiveness of 
interventions that target drug supply (e.g. law 
enforcement) or drug demand (e.g. prevention 
programmes or public health campaigns) has not yet 
been explored. In order to start exploring these potential 
wastewater-based epidemiology applications, a close 
collaboration between the different stakeholders 
involved, including epidemiologists, legal authorities and 
the scientists applying wastewater analysis, is highly 
recommended.
Further developments can be expected with regard to 
widening the application of this interdisciplinary 
approach within more holistic epidemiological studies of 
societal health. In fact, wastewater-based epidemiology 
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Appendix
A list of all the studies on wastewater-based epidemiology published by early 2015 is presented here. Studies in bold 
are those that report information on illicit drug use.
Study Country Substances investigated Application 
Jones-Lepp et al., 
2004
United States Methamphetamine, MDMA Presence in effluents from three wastewater 
treatment plants in Nevada, Utah and South 
Carolina
Zuccato et al., 2005 Italy Cocaine, benzoylecgonine Estimation of cocaine use in four Italian cities
Castiglioni et al., 
2006
Italy, Switzerland Cocaine and metabolites, 
amphetamines, opioids, cannabinoids
Presence in influents and effluents from two 
wastewater treatment plants in Milan and Lugano
Hummel et al., 2006 Germany Benzoylecgonine, opioids Presence in influents and effluents from 12 
wastewater treatment plants and 11 rivers
Huerta-Fontela et al., 
2007
Spain Cocaine, amphetamines, ketamine, 
LSD, PCP, fentanyl
Presence in influents and effluents from 16 
wastewater treatment plants and six rivers in 
Catalonia
Bones et al., 2007 Ireland Cocaine, benzoylecgonine Estimation of cocaine use in Dublin and 
surroundings
Boleda et al., 2007 Spain Opioids, tetrahydrocannabinol, fentanyl Presence in influents and effluents from five 
wastewater treatment plants in Catalonia
Zuccato et al., 2008 Italy, 
Switzerland, 
United Kingdom
Cocaine, heroin, amphetamines, 
cannabis
Back-calculation of consumption in three cities 
(Milan, Lugano and London)—comparison with 
prevalence data
Gheorghe et al., 
2008
Belgium Cocaine, benzoylecgonine, ecgonine 
methyl ester
Presence in five wastewater treatment plants and 
three rivers
Kasprzyk-Hordern et 
al., 2008
England Cocaine, benzoylecgonine, 
amphetamine
Presence in influent and effluent from one 
wastewater treatment plant and one river
Postigo et al., 2008 Spain Cocaine, benzoylecgonine, 
amphetamines, opioids, cannabinoids, 
LSD
Presence in influents and effluents from four 
wastewater treatment plants on the east coast
Huerta-Fontela et 
al., 2008
Spain Cocaine, amphetamines, ketamine Presence in 42 wastewater treatment plants 
(influents and effluents) and loads per capita in 
north-east Spain
Kasprzyk-Hordern 
et al., 2008
United States Cocaine and metabolites, 
amphetamines, ketamine, PCP
Calculation of loads (mg/person/day) in seven 
wastewater treatment plants
van Nuijs et al., 
2009
Belgium Cocaine, benzoylecgonine Back-calculation of cocaine consumption from 
41 wastewater treatment plants
Bijlsma et al., 2009 Spain Cocaine and metabolites, 
amphetamines, THC-COOH
Presence in influent and effluent from one 
wastewater treatment plant (weekdays and 
weekends) in Castellon
Bartelt-Hunt et al., 
2009
United States Amphetamine, methamphetamine Presence in effluent from one wastewater 
treatment plant and four rivers in Nebraska
Cecinato et al., 2009 Italy, Portugal, 
Serbia, Algeria, 
Chile, Brazil
Cocaine Presence in airborne particles
Kasprzyk-Hordern 
et al., 2009
United Kingdom Cocaine, benzoylecgonine, 
amphetamine
Back-calculation of cocaine use in two 
wastewater treatment plants in South Wales
Mari et al., 2009 Italy Cocaine, heroin Calculation of loads in one wastewater treatment 
plant in Florence
Banta-Green et al., 
2009
United States Cocaine, methamphetamine, MDMA Calculation of index loads (mg/person/day) in 96 
municipalities in the state of Oregon
Gonzalez-Marino et 
al., 2009
Spain Amphetamines Presence in influents and effluents from four 
wastewater treatment plants in north-west Spain
Postigo et al., 2010 Spain Cocaine, amphetamines, heroin, 
cannabis
Estimation of consumption based on seven 
wastewater treatment plants in north-east Spain
Terzic et al., 2010 Croatia Cocaine, amphetamines, heroin, 
cannabis
Estimation of consumption based on one 
wastewater treatment plant in Zagreb 
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Karolak et al., 2010 France Cocaine, MDMA Estimation of consumption based on four 
wastewater treatment plants in Paris
Metcalfe et al., 2010 Canada Cocaine, amphetamines Estimation of consumption based on three 
wastewater treatment plants
Berset et al., 2010 Switzerland Cocaine, amphetamines, opioids Presence in influents and effluents from five 
wastewater treatment plants 
Gonzalez-Marino et 
al., 2010 
Spain Cocaine, amphetamines, opioids, 
cannabis
Presence in influents and effluents from five 
wastewater treatment plants and four rivers in 
north-west Spain
Zuccato et al., 2011 Italy Cocaine, heroin, amphetamines and 
cannabis
A 4-year monitoring campaign for estimation of 
use in the north of Italy
Reid et al., 2011a Norway Benzoylecgonine, methamphetamine Estimation of consumption based on one 
wastewater treatment plant in Oslo
Irvine et al., 2011 Australia Benzoylecgonine, methamphetamine, 
MDMA
Estimation of consumption based on four 
metropolitan and three regional plants in South 
Australia
Postigo et al., 2011 Spain Cocaine, cannabis, opioids, 
amphetamines, LSD
Estimation of consumption in a prison in 
Catalonia
van Nuijs et al., 
2011
Belgium Cocaine, amphetamines, heroin A 1-year estimation campaign in Brussels
Gerrity et al., 2011 United States Cocaine, amphetamines, morphine Estimation of use during a sporting event (the 
National Football League Super Bowl)
Lai et al., 2011 Australia Cocaine, amphetamines, THC-COOH Estimation of use based on one wastewater 
treatment plant in South-East Queensland
Reid et al., 2011b Norway Cocaine, amphetamines Estimation of use in different city locations and 
during special events in Oslo
Kasprzyk-Hordern 
and Baker, 2012
United Kingdom Amphetamine, methamphetamine, 
MDMA, MDA
Profile of chiral drugs in wastewater 
Prichard et al., 2012 Australia Cocaine, methamphetamine, MDMA, Estimation of use in two consecutive years (2009 
and 2010)
Baker et al., 2012 Czech Republic Cocaine and metabolites, MDMA Estimation of use based on one wastewater 
treatment plants (1-week monitoring)
Bijlsma et al., 2012 The Netherlands Cocaine, amphetamines, ketamine, 
opioids, THC-COOH
Presence in influents and effluents from five 
wastewater treatment plants 
Brewer et al., 2012 United States Cocaine, benzoylecgonine Estimation of use in one municipality
Thomas et al., 2012 Europe (19 
cities)
Cocaine, amphetamines, cannabis Estimation of use in 19 European cities
Lai et al., 2013a Australia Cocaine, methamphetamine, MDMA, 
cannabis
Estimation of use during holidays in urban, rural 
and vacation areas
van Nuijs et al., 2014 Belgium Mephedrone, ketamine, MDPV, 
cannabis
Monitoring in three wastewater treatment plants
Reid et al., 2013 Norway Cathinone, mephedrone, PMA, PMMA, 
synthetic cannabinoids
Monitoring in three Norwegian cities
Burgard et al., 2013 United States Amphetamine Presence in wastewater from a college campus 
Repice et al., 2013 Italy 12 licit and illicit drugs Presence in a wastewater treatment plant in 
Verona, Italy
Chen et al., 2013 Australia MDMA, cathinones Estimation of use in a 3-year campaign in 
Adelaide
Lai et al., 2013b Asia Cocaine, MDMA, methamphetamine, 
ketamine 
Estimation of use in the largest wastewater 
treatment plant in Hong Kong
Lai et al., 2013 c Australia Cocaine, methamphetamine, MDMA, 
cannabis, benzylpiperazine, 
mephedrone, methylone
Estimation of use at an annual music festival
Nefau et al., 2013 France Cocaine, MDMA, amphetamine, 
cannabis, methadone
Estimation in 25 wastewater treatment plants 
Mwenesongole et al., 
2013
United Kingdom New synthetic drugs, amphetamine, 
methamphetamine, cocaine
Screening of 25 drugs in wastewater from 
Cambridgeshire
Yargeau et al., 2014 Canada Amphetamine, methamphetamine, 
MDMA, cocaine, heroin, ketamine
Estimation of use in two Canadian cities
Brewer et al., 2014 United States Cocaine, methamphetamine Estimation of use in a prison
Subedi and Kannan, 
2014
United States Cocaine, amphetamine, 
methamphetamine, MDMA, 
methadone, morphine
Estimation of mass loads in two wastewater 
treatment plants in the Albany area, New York 
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Study Country Substances investigated Application 
Khan et al., 2014 Asia Benzoylecgonine, amphetamine, 
MDMA, methamphetamine, 
ketamine, methadone, heroin, 
THC-COOH
Estimation of use in four Chinese megacities
Li et al., 2014 Asia Amphetamine and 
methamphetamine
Estimation of use in Beijing
Mackulak et al., 
2014
Slovakia Cocaine, amphetamine, 
methamphetamine, MDMA, cannabis
Estimation of use in eight cities 
Östman et al., 2014 Sweden Benzoylecgonine, amphetamine, 
MDMA, methamphetamine, codeine, 
morphine, methadone, EDDP
Estimation of use in 33 municipalities
Kankaanpaa et al., 
2014
Finland Benzoylecgonine, amphetamine, 
MDMA, methamphetamine, 
methadone, MDPV
Estimation of use in 10 municipalities
Vuori et al., 2014 Finland Benzoylecgonine, amphetamine, 
MDMA, methamphetamine, 
methadone, MDPV, THC-COOH
Estimation of use in nine municipalities
Damien et al., 2014 Martinique, 
Caribbean
Cocaine Estimation of quantity used based on four 
wastewater treatment plants
Kim et al., 2015 South Korea Amphetamine, methamphetamine, 
codeine
Estimation of use in five South Korean cities
EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; LSD, lysergic acid diethylamide; MDA, 3,4-methylenedioxyamphetamine; MDPV, methylene-
dioxypyrovalerone; PCP, phencyclidine; PMA, para-methoxyamphetamine; PMMA, para-methoxy-N-methylamphetamine; THC-COOH, 11-nor-9-car-
boxy-delta-9-tetrahydrocannabinol. 
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